Compositions and methods for improving the presentation of vaccine epitopes

Fusion proteins combining vaccine epitopes with C-degron peptides enhance antigen presentation by targeting ubiquitin ligases, addressing the challenge of inducing effective immune responses, resulting in improved T cell-mediated immunity against infectious diseases and cancer.

WO2024249785A2PCT designated stage expired Publication Date: 2024-12-05ST PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/031904
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current methods face challenges in inducing an effective T cell-mediated immune response against vaccine epitopes, particularly for infectious diseases and cancer, as they struggle to efficiently present vaccine epitopes to antigen-presenting cells.

Method used

The development of fusion proteins comprising a vaccine epitope and a C-degron peptide, which enhances epitope presentation by targeting ubiquitin ligases for efficient degradation and processing, thereby increasing immune response through enhanced antigen presentation.

Benefits of technology

This approach significantly improves the presentation of vaccine epitopes, leading to increased CD4+ and CD8+ T cell responses and antibody production, effectively preventing or reducing the severity of associated diseases, including cancers and infectious diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024031904_05122024_PF_FP_ABST
    Figure US2024031904_05122024_PF_FP_ABST
Patent Text Reader

Abstract

Provided are compositions and methods for improving the presentation of vaccine epitopes. Provided are fusion proteins comprising a vaccine epitope and a C-degron peptide. Also provided are nucleic acid molecules, such as circular RNA molecules, encoding the fusion proteins, and related methods and uses, including therapeutic and prophylactic methods and uses, for example for enhancing vaccine epitope presentation and for vaccinating a subject. In some aspects, vaccine epitopes include an infectious disease vaccine epitope or a cancer vaccine epitope.
Need to check novelty before this filing date? Find Prior Art

Description

COMPOSITIONS AND METHODS FOR IMPROVING THE PRESENTATION OF VACCINE EPITOPESCross-Reference to Related Applications

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 505,981, filed June 2, 2023, entitled “COMPOSITIONS AND METHODS FOR IMPROVING THE PRESENTATION OF VACCINE EPITOPES”, which is hereby incorporated herein by reference in its entirety.Field

[0002] The present disclosure relates to compositions and methods for improving the presentation of vaccine epitopes. Provided are fusion proteins comprising a vaccine epitope and a C-degron peptide. Also provided are nucleic acid molecules, such as circular RNA molecules, encoding the fusion proteins, and related methods and uses, including therapeutic and prophylactic methods and uses, for example for enhancing vaccine epitope presentation and for vaccinating a subject. In some aspects, vaccine epitopes include an infectious disease vaccine epitope or a cancer vaccine epitope.Background

[0003] In professional antigen-presenting cells (APCs) such as dendritic cells (DCs), antigen epitopes are presented via the major histocompatibility complex I (MHC I) and MHC II molecules to stimulate CD8+and CD4+ T cells, respectively. Challenges exist in producing an effective immune response against various vaccine epitopes, particularly for a T cell-mediated response. There remains a need for an efficient method for increasing T cell-mediated responses against vaccine epitopes. Provided herein are embodiments that meet such needs.Summary

[0004] Provided herein are fusion proteins fusion protein comprising a vaccine epitope and a C-degron peptide.

[0005] In some of any embodiments, the C-degron peptide is at least 2 amino acids in length. In some of any embodiments, the C-degron peptide is at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids in length. In some of any embodiments, the C- degron peptide is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids in length.

[0006] In some of any embodiments, the C-degron peptide comprises an E3 ubiquitin ligase target motif. In some of any embodiments, the E3 ubiquitin ligase target motif comprises a target motif of DoalO, MARCHF6, CRL2, NOT4, ELOB, ELOC, DDB1, CUL2, CUL4, KLHDC1, KLHDC2, KLHDC3, KLHDC10, FEM1A, FEM1B, FEM1C, APPBP2, DCAF12, TRPC4AP, UBC6, UBC7, UBR1, UBR2, UBR4, and / or UBR5. In some of any embodiments, the E3 ubiquitin ligase target motif comprises a target motif of DoalO or MARCHF6.

[0007] In some of any embodiments, the C-degron peptide comprises an FSSL-like sequence. In some of any embodiments, the C-degron peptide comprises the following formula: [F,W or Y]-[S or T]-[S or T]-[I, L or V]-XX-[hydrophobic]-X-[I, L or V]-[H-bond acceptor], wherein X is any ammo acid.

[0008] In some of any embodiments, the C-degron peptide comprises a CL1, a CL2, a CL6, a CL9, a CLIO, a CL11, a CL12, a CL15, or a CL16 sequence or a variant thereof. In some of any embodiments, the C-degron peptide comprises the sequence set forth in any one of SEQ ID NOS: 1 and 39-46, a contiguous portion of any one of SEQ ID NOS: 1 and 39-46 of at least 4 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing.

[0009] In some of any embodiments, the C-degron peptide comprises a CL1 sequence or a variant thereof. In some of any embodiments, the C-degron peptide comprises the sequence set forth in SEQ ID NO: 1, a contiguous portion of SEQ ID NO: 1 of at least 4 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing.

[0010] In some of any embodiments, the fusion protein also comprises one or more additional vaccine epitopes.

[0011] In some of any embodiments, the C-degron peptide is located C-terminal to the vaccine epitopes.

[0012] In some of any embodiments, the vaccine epitope comprises an infectious disease vaccine epitope, optionally a viral vaccine epitope.

[0013] In some of any embodiments, the vaccine epitope comprises a cancer epitope. In some of any embodiments, the cancer epitope is a cancer neoantigen epitope. In some of any embodiments, the cancer neoantigen epitope comprises a cancer epitope selected from among MEI, M26, Gludl, Mtchl, M18, and E2f8. In some of any embodiments, the vaccine epitope independently comprises a sequence selected from the sequence set forth in SEQ ID NOS:2-8, a contiguous portion of a sequence selected from the sequence set forth in SEQ ID NOS:2-8 of at least 8 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing.

[0014] In some of any embodiments, the fusion protein also comprises one or more peptide linkers. In some of any embodiments, the one or more peptide linkers are located between the vaccine epitope and the C-degron peptide. In some of any embodiments, the one or more peptide linkers are located between different vaccine epitopes.

[0015] In some of any embodiments, the one or more peptide linkers independently comprises a natural linker comprising 5 or more adjacent amino acids that naturally occur in the N- terminal or C-terminal of the vaccine epitope. In some of any embodiments, the one or more peptide linkers independently comprises a natural linker comprising 8, 9, 10, 11, 12, 13, 14, 15, or 16 or more adjacent amino acids that naturally occur in the N- terminal or C-terminal of the vaccine epitope. In some of any embodiments, the one or more peptide linkers independently comprises the sequence set forth in any one of SEQ ID NOS:28-38, a contiguous portion of anyone of SEQ ID NOS:28-38 of at least 8 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing.

[0016] In some of any embodiments, when the fusion protein is expressed in a subject, an immune response to the vaccine epitope is increased compared to a subject without expression of the fusion protein.

[0017] In some of any embodiments, the immune response comprises CD4+ T cell response, CD8+ T cell response and / or antibody response. In some of any embodiments, the immune response comprises CD4+ T cell response or CD8+ T cell response.

[0018] Also provided are nucleic acid constructs encoding any of the provided fusion proteins.

[0019] In some of any embodiments, the nucleic acid construct also comprises a translation initiation element. In some of any embodiments, the translation initiation element is an internal ribosome entry site (IRES) or a Translation Initiator of Short 5' UTR (TISU) element. In some of any embodiments, the translation initiation element comprises the sequence set forth in SEQ ID NO:27, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to the sequence set forth in SEQ ID NO:27.

[0020] In some of any embodiments, the nucleic acid comprises an RNA. In some of any embodiments, the nucleic acid comprises a circular RNA. In some of any embodiments, the nucleic acid comprises a linear RNA. In some of any embodiments, the nucleic acid comprises a cleaved linear RNA comprising a hydroxyl group at the 5' terminus, and a 2',3'-cyclic phosphate at the 3' terminus. In some of any embodiments, the nucleic acid comprises a messenger RNA.

[0021] In some of any embodiments, the nucleic acid comprises DNA.

[0022] Also provided are compositions comprising any of the provided fusion proteins or any of the provided nucleic acid constructs. In some of any embodiments, the composition is a pharmaceutical composition. In some of any embodiments, the composition comprises a pharmaceutically acceptable excipient.

[0023] In some of any embodiments, the composition comprises a lipid nanoparticle (LNP).

[0024] In some of any embodiments, the composition comprises a lipoplex (LPX).

[0025] Also provided are methods of vaccinating a subject, that involves administering any of the provided fusion proteins, any of the provided nucleic acid constructs, or any of the provided compositions, to the subject.

[0026] Also provided are methods for enhancing vaccine epitope presentation to elicit an immune response in the subject, that involves administering any of the provided fusion proteins, any of the provided nucleic acid constructs, or any of the provided compositions, to the subject.

[0027] In some of any embodiments, the subject has a disease or disorder.

[0028] Also provided are methods of treating a disease or disorder in the subject, that involves administering any of the provided fusion proteins, any of the provided nucleic acid constructs, or any of the provided compositions, to the subject.

[0029] In some of any embodiments, an immune response to the vaccine epitope is increased compared to a subject without expression of the fusion protein. In some of anyembodiments, the immune response comprises CD4+ T cell response, CD8+ T cell response and / or antibody response. In some of any embodiments, the immune response comprises CD4+ T cell response or CD8+ T cell response.

[0030] In some of any embodiments, the method prevents or reduces the severity of a disease or disorder associated with the vaccine epitope in the subject.

[0031] In some of any embodiments, the disease or disorder is an infectious disease, optionally a viral infection.

[0032] In some of any embodiments, the disease or disorder is cancer.

[0033] Also provided are any of the provided fusion proteins, any of the provided nucleic acid constructs, or any of the provided compositions for use in vaccinating a subject, wherein the fusion protein, the nucleic acid construct or the composition is administered to the subject.

[0034] Also provided are any of the provided fusion proteins, any of the provided nucleic acid constructs, or any of the provided compositions for use in enhancing an immune response to a vaccine epitope in a subject, wherein the fusion protein, the nucleic acid construct or the composition is administered to the subject.

[0035] Also provided are any of the provided fusion proteins, any of the provided nucleic acid constructs, or any of the provided compositions for use in treating a disease or disorder in a subject, wherein the fusion protein, the nucleic acid construct or the composition is administered to the subject.

[0036] Also provided are uses of any of the provided fusion proteins, any of the provided nucleic acid constructs, or any of the provided compositions in the manufacture of medicament for vaccinating a subject, wherein the medicament is administered to the subject.

[0037] Also provided are uses of any of the provided fusion proteins, any of the provided nucleic acid constructs, or any of the provided compositions in the manufacture of medicament for enhancing an immune response to a vaccine epitope in a subject, wherein the medicament is administered to the subject.

[0038] Also provided are uses of any of the provided fusion proteins, any of the provided nucleic acid constructs, or any of the provided compositions in the manufacture of medicament for treating a disease or disorder in a subject, wherein the medicament is administered to the subject.Brief Description of the Drawings

[0039] FIG. 1 shows a schematic of antigen / epitope processing and presentation and the ubiquitin and proteasome-mediated protein degradation pathways.

[0040] FIG. 2A shows a schematic of exemplary fusion protein constructs encoding cancer neoantigen epitopes and an exemplary C-degron peptide CL1 (NeoAg-CLl); neoantigen epitopes alone (NeoAg) or neoantigen epitopes and an MHC class I trafficking signal (NeoAg- MITD). FIG. 2B shows chromatographs from the purification of circular RNA constructs from FIG. 2A and the efficiency of RNA circularization.

[0041] FIG. 3 shows the luciferase activity from the liver, lung and spleen from mice administered lipoplex (LPX) containing RNA constructs encoding a firefly luciferase.

[0042] FIG. 4A shows the weight of the spleen from mice administered lipoplex (LPX) containing RNA constructs from FIG. 2A. FIG. 4B shows the IFN-y production from splenocytes from mice administered LPX containing RNA constructs from FIG. 2A, after stimulation with the neoepitope MEL FIG. 4C shows the IFN-y production from splenocytes from mice administered LPX containing RNA constructs from FIG. 2A, after stimulation with the neoepitope AHL FIG. 4D shows the IFN-y production from splenocytes from mice administered LPX containing RNA constructs from FIG. 2A, after stimulation with the neoepitope Mtchl. FIG. 4E shows the IFN-y production from splenocytes from mice administered LPX containing RNA constructs from FIG. 2A, after stimulation with the neoepitope E2f8. FIG. 4F shows the IFN-y production from splenocytes from mice administered LPX containing RNA constructs from FIG. 2A, after stimulation with the neoepitope Gludl.

[0043] FIG. 5A shows a schematic of exemplary fusion protein constructs encoding cancer neoantigen epitopes and an exemplary C-degron peptide CL1 (NeoAg-CLl), in which the neoantigen epitopes are connected with a 10-mer non-immunogenic glycine / senne linker (GS linker) or natural sequences at the N- and C-terminus of each neoepitope (natural linkers). FIG. 5B shows chromatographs from the purification of circular RNA constructs from FIG. 5A and the efficiency of RNA circularization. FIG. 5C shows the IFN-y production from splenocytes from mice administered LPX containing RNA constructs from FIG. 5A, after stimulation with the neoepitope MEL FIG. 5D shows the IFN-y production from splenocytes from miceadministered LPX containing RNA constructs from FIG. 5A, after stimulation with the neoepitope AHI.

[0044] FIG. 6A shows a schematic of an exemplary circular RNA construct encoding cancer neoantigen epitopes linked with natural sequences at the N- and C-terminus of each neoepitope and an exemplary C-degron peptide CL1 (NeoAg-CLl circRNA) and a linear mRNA encoding the neoantigen epitopes linked with natural sequences at the N- and C- terminus of each neoepitope and an MHC class I trafficking signal (NeoAg-MITD mRNA). FIG. 6B shows the weight of the spleen from mice administered lipoplex (LPX) containing RNA constructs from FIG. 6A. FIG. 6C shows the IFN-y production from splenocytes from mice administered LPX containing RNA constructs from FIG. 6A, after stimulation with the neoepitope MEL FIG. 6D shows the IFN-y production from splenocytes from mice administered LPX containing RNA constructs from FIG. 6A, after stimulation with the neoepitope AHI. FIG. 6E shows the IFN-y production from splenocytes from mice administered LPX containing RNA constructs from FIG. 6A, after stimulation with the neoepitope E2f8.

[0045] FIG. 7A shows a schematic of a dosing schedule of administrations with LPX containing circRNA encoding cancer neoepitopes fused to an exemplary C-degron CL1 (NeoAg-CLl), an anti-PD-1 antibody (PD-1 Ab), or a combination of both. FIG. 7B shows tumor size over time following the administration as depicted in FIG. 7 A. FIG. 7C shows survival curve over time following the administration as depicted in FIG. 7A. FIG. 7D shows the IFN-y production from splenocytes from mice following the administration as depicted in FIG. 7 A, after stimulation with the neoepitope MEL FIG. 7E shows the IFN-y production from splenocytes from mice following the administration as depicted in FIG. 7A, after stimulation with the neoepitope AHLDetailed Description

[0046] Provided herein are fusion proteins, nucleic acid constructs, and / or compositions for improving the presentation of vaccine epitopes. In some embodiments, the fusion proteins comprise a vaccine epitope and a C-degron peptide. In some aspects, the C-degron peptide enhances the presentation of the fused vaccine epitope to elicit immune responses against thevaccine epitope. In some aspects, also provided are methods and uses, including prophylactic and therapeutic methods and uses, such as vaccination methods, that employ any of the fusion proteins, nucleic acid constructs or compositions. Also provided are methods and uses of the provided fusion proteins, nucleic acid constructs, and / or compositions such as in therapeutic and prophylactic uses, such as in treating a disease or disorder or vaccination of a subject. The methods and uses provided herein may be applicable for treating various patients with different diseases, developing therapeutics, and / or developing vaccines against various diseases, including infectious diseases and cancers. Also provided are methods for producing the fusion proteins, nucleic acid constructs and compositions.

[0047] In some aspects, the provided embodiments can result in improved vaccine epitope presentation, increase in anti-vaccine epitope immune response, improved vaccination and improved therapeutic outcome (e.g., anti-cancer therapy). In some contexts, the provided embodiments, including combination therapy, result in increased efficiency of the vaccine epitope presentation and can lead to improved induction of an immune response, including CD4+ and CD8+ T cell response against the vaccine epitopes, and / or prevents or reduces the severity of a disease or disorder associated with the vaccine epitope in the subject.

[0048] In some aspects, the provided embodiments offer various advantages and improvements in producing immune responses against the vaccine epitopes in general and particularly for epitope-specific T cell activity, for therapy and / or vaccination.

[0049] Further, the provided embodiments were observed to improve anti-cancer therapy, by reducing the tumor size and increasing the survival of subjects administered constructs encoding cancer neoantigen epitopes fused to a C-degron, particularly in combination with another anti-cancer therapeutic such as a checkpoint inhibitor. As described herein, when administered in combination with an immune checkpoint inhibitor therapy, cancer vaccine constructs encoding neoantigen epitope-C-degron fusion proteins showed substantial improvements in inhibiting tumor grow th and survival, by promoting neoepitope-specific T cell response. In some aspects, the provided embodiments are based on these observations showing substantially improved therapeutic outcome, particularly those that have been difficult using existing approaches, such as anti-cancer vaccination. The provided fusion proteins, nucleic acid constructs, including circular RNA constructs, and compositions, including lipid nanoparticle compositions, can be employed in various therapeutic and prophylactic uses, including forexample infectious disease vaccines, cancer vaccines, immunotherapy, autoantigen vaccines, gene therapy, gene editing and others.

[0050] All publications, including patent documents, scientific articles and databases, referred to in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication were individually incorporated by reference. If a definition set forth herein is contrary to or otherwise inconsistent with a definition set forth in the patents, applications, published applications and other publications that are herein incorporated by reference, the definition set forth herein prevails over the definition that is incorporated herein by reference.

[0051] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.I. FUSION PROTEINS FOR ENHANCING VACCINE EPITOPE PRESENTATION

[0052] Provided herein are fusion proteins, nucleic acid constructs, compositions, and methods that relate to enhancing the efficiency of vaccine epitope presentation, and in some aspects, immune response against the vaccine epitope. The present disclosure in certain aspects relates to improved efficiency of various fusion proteins and nucleic acid molecules encoding fusion proteins of one or more vaccine epitopes and a C-degron peptide, to induce vaccine epitope-specific immune responses. Features of exemplary fusion proteins, nucleic acid constructs, and / or compositions are described herein.

[0053] In some aspects, the provided embodiments results in improved presentation of vaccine epitopes, such as epitopes from cancer antigens, or infectious disease vaccine epitopes, by improving the antigen / epitope processing and presentation by antigen presenting cells. In some aspects, the C-degron peptide, which is fused to the one or more vaccine epitopes, can help the fusion protein containing one or more vaccine epitopes, be targeted by ubiquitin ligases such as E3 ligases, for example MARCHF6 or DoalO. In some aspects, as described herein, targeting of the fusion protein comprising one or more vaccine epitopes, by the ubiquitin- proteasome components such as E3 ligases, can help epitope processing and presentation of epitopes by the major histocompatibility complex (MHC).

[0054] In some aspects, human leukocyte antigens (HLA) are expressed as cell surface receptors that present antigenic peptides (i.e., epitopes) to T cells in a restricted manner, whichin some cases allows discrimination between self and foreign antigens. The HLA complex is a complex of genes on chromosome 6 that encodes the cell-surface proteins responsible for the regulation of the immune system. In some aspects, the human major histocompatibility complex (MHC) is residence to HLA genes that play a fundamental role in the acceptance of transplanted tissues. The MHC contains many of the genes associated with cell-mediated immune defenses. The MHC complex encodes the a-chains of the MHC class I molecules HLA- A, HLA-B, and HLA-C (alleles) and the a- and P-chains of the MHC class II molecules HLA-DR, HLA-DP, and HLA-DQ (allotypes), all of which are expressed in a co-dominant fashion.

[0055] In humans, the MHC is divided into three regions: Class I, II, and III. The A, B, and C genes belong to MHC class I, whereas the six D genes belong to class II. MHC class I molecules are made of a single polymorphic chain containing 3 domains (alpha 1, 2 and 3), which associates with beta 2 microglobulin at cell surface. Class II molecules are made of 2 polymorphic chains, each containing 2 chains (alpha 1 and 2, and beta 1 and 2). Class I MHC molecules are expressed on virtually all nucleated cells.

[0056] In some contexts, peptide fragments presented in the context of class I MHC molecules are recognized by CD8+ T lymphocytes (cytolytic T lymphocytes or CTLs). CD8+ T lymphocytes frequently mature into cytolytic effectors which can lyse cells bearing the stimulating antigen. Class II MHC molecules are expressed primarily on activated lymphocytes and antigen-presenting cells. CD4+ T lymphocytes (helper T lymphocytes or Th) are activated with recognition of a unique peptide fragment presented by a class II MHC molecule, usually found on an antigen-presenting cell like a macrophage or dendritic cell. CD4+ T lymphocytes proliferate and secrete cytokines such as IL-2, IFN-gamma and IL-4 that support antibody- mediated and cell mediated responses.

[0057] In some aspects, functional HLAs are characterized by a deep binding groove to which endogenous as well as foreign, potentially antigenic peptides bind. The groove is further characterized by a well-defined shape and physicochemical properties. HLA class I binding sites are closed, in that the peptide termini are pinned down into the ends of the groove. They are also involved in a network of hydrogen bonds with conserved HLA residues. In view of these restraints, the length of bound peptides is limited to 8-10 residues. However, it has been demonstrated that peptides of up to 12 amino acid residues are also capable of binding HLAclass I. Comparison of the structures of different HLA complexes confirmed a general mode of binding wherein peptides adopt a relatively linear, extended conformation, or can involve central residues to bulge out of the groove.

[0058] In contrast to HLA class I binding sites, class II sites are open at both ends. This allows peptides to extend from the actual region of binding, thereby “hanging out” at both ends. Class II HLAs can therefore bind peptide ligands of variable length, ranging from 9 to more than 25 amino acid residues. Similar to HLA class I, the affinity of a class II ligand is determined by a “constant” and a “variable” component. The constant part again results from a network of hydrogen bonds formed between conserved residues in the HLA class II groove and the main-chain of a bound peptide. However, this hydrogen bond pattern is not confined to the N- and C-terminal residues of the peptide but distributed over the whole chain. The latter is important because it restricts the conformation of complexed peptides to a strictly linear mode of binding. This is common for all class II allotypes. The second component determining the binding affinity of a peptide is variable due to certain positions of polymorphism within class II binding sites. Different allotypes form different complementary pockets within the groove, thereby accounting for subtype-dependent selection of peptides, or specificity. In some aspects, he constraints on the amino acid residues held within class II pockets are in general “softer” than for class I. There is much more cross reactivity of peptides among different HLA class II allotypes.

[0059] In professional antigen-presenting cells like dendritic cells (DCs), ubiquitindependent proteasomal degradation of foreign proteins can mediate antigen presentation through MHC-I and MHC-II molecules to stimulate CD8+ and CD4+ T cells, respectively. In some aspects, activation of helper T (Th) cells upon recognition of the presented peptide fragments of a protein antigen (i.e., epitopes), which are bound to MHC class II (MHC-II) or MHC class I (MHC-I) molecules of antigen-presenting cells, results in the development of antigen-reactive antibodies, or antigen-specific T cell response. In some aspects, the processing of the antigen into peptide epitopes and the binding of the peptide epitope to an MHC molecule at a sufficient affinity is a prerequisite for immunogenicity, i.e., the ability of a peptide to trigger an immune response.A. Ubiquitin Ligases and Proteosome Degradation

[0060] Provided herein are fusion proteins that enhance ubiquitin ligase activity and proteosome degradation of the fusion protein. In some aspects, the fusion proteins comprise a C-degron fused to one or more vaccine epitopes. Also provided herein are methods for enhanced epitope presentation through efficient degradation and processing of the vaccine epitopes of the fusion protein via the ubiquitin degradation system.

[0061] In eukaryotic cells, various proteins are degraded by the ubiquitin system. The ubiquitin system tags unstable proteins for degradation through ligation of ubiquitin. Ubiquitin- activating enzymes form a high-energy thiol ester bond with the C-terminus of ubiquitin which is subsequently transferred to the thiol of a ubi quitin-conjugating enzyme. In some aspects, the ubi quitin-activating enzyme is El or UBA. In some aspects, the ubiquitin-conjugating enzyme targeting the fusion protein is E2 or UBC. Ubiquitin is then transferred from the ubiquitin- conjugating enzyme to the target protein. In some aspects, the transfer of ubiquitin to the target protein is carried out by a ubiquitin protein ligase. In some aspects, the transfer of ubiquitin to the fusion protein is not assisted by a ubiquitin protein ligase. In some aspects, the ubiquitin protein ligase is an E3 ligase. In some aspects, the E3 ubiquitin protein ligase is classified as a really interesting new gene (RING), the homologous to the E6-AP carboxyl terminus (HECT), or the RING-between-RING (RBR). In some aspects, the E3 ligase is a RING. In some aspects, the E3 ligase is a HECT. In some aspects, the E3 ligase is an RBR.

[0062] In some aspects, the E2 ubiquitin-conjugating enzymes Ubc6 and Ubc7 are involved in degradation of soluble and integral membrane proteins (Khmelinskii et al., 2014 Nature, 576(7531), 410-413). In yeast, Ubc6 and Ubc7 are involved in operating ER-associated protein degradation (ERAD) pathways with the integral membrane E3 ubiquitin ligases Asi, Hrdl, and DoalO.

[0063] In some aspects, the RING E3 ligase targeting the fusion protein is a Membrane- associated RING-CH-type finger (MARCH) protein. In some aspects, MARCH proteins contain a C4HC3-type RING domain that has minor difference with the classic C3HC4-type RING domain in the identities of the fourth and fifth coordinating residues and the length of the peptide segments between the two. In some aspects, the MARCH proteins targeting the fusion protein are located in distinct cellular compartments, including the endosomes, lysosomes, endoplasmic reticulum (ER), Golgi apparatus, cytosol and plasma membrane. In some aspects,the MARCH protein contains a RING-CH domain and a transmembrane domain. In some aspects, the MARCH protein targeting the fusion protein is MARCH 1, MARCH2, MARCH3, MARCH4, MARCH5, MARCH6, MARCH7, MARCH8, MARCH9, MARCH10 or MARCH1 1. In some aspects, the MARCH protein targeting the fusion protein is MARCH6. In some aspects, MARCH6 is an ER-resident ubiquitin ligase involved in ER-associated degradation (ERAD). E2 ubiquitin-conjugating enzymes Ubc6 and Ubc7 degrade soluble and integral membrane proteins. In some aspects, Ubc6 and Ubc7 are involved in operating ER- associated protein degradation (ERAD) pathways with the integral membrane E3 ubiquitin ligase MARCH6.

[0064] In some cases, repeated cycles of ubiquitination attach a multiubiquitin chain to the target protein, leading to proteosome-mediated protein degradation.B. C-degron Peptides

[0065] In some aspects, certain sequence elements or structural motifs of target proteins act as degradation signals which mark the proteins for ubiquitination by a particular branch of the ubiquitin system for subsequent degradation. In some aspects, an exemplary a sequence element that can target the protein for degradation is a degron.

[0066] In some embodiments, enhanced presentation of vaccine epitope is achieved by fusing the vaccine epitope sequences with a degron, to allow recruitment to the endogenous protein turnover machinery and subsequent degradation of the fusion protein. In some aspects, mechanisms for targeted protein degradation include, but are not limited to, recruitment to an E3 ligase for ubiquitination and subsequent proteasomal degradation, direct recruitment to the proteasome, and recruitment to the lysosome. In some embodiments, the fusion protein includes specific sequence elements or motifs (e.g., degron) selectively recognized by E3 ligases. In some embodiments, the fusion protein includes specific sequence elements or motifs (e.g., degron) selectively recognized by a Membrane-associated RING-CH-type finger protein 6 (MARCH6; also called MARCHF6). In some embodiments, the degron is capable of targeting fusion proteins containing the vaccine epitopes for degradation e.g., through a ubiquitination pathway), inducing protein degradation, or degrading proteins. In some aspects, the attachment of the degron, such as a C-degron peptide, facilitates the processing and presentation of thevaccine epitopes of the fusion protein, and ultimately results in an increase in immune response against the vaccine epitopes by virtue of enhanced antigen presentation.

[0067] In some aspects, C-terminal sequences of certain proteins, in some cases varying froml6 to 50 amino acid residues, can contain degradation signals channeling proteins for degradation via the Ubc6 and / or Ubc7 sub-pathways of the ubiquitin system. In some cases, certain C-terminal sequences share similar sequence motifs, and a feature common to almost all of these sequences is a highly hydrophobic region such as is usually located inside globular proteins or inserted into membranes. In some aspects, the degron is a C-degron, located at or near the C-terminus of the protein. In some aspects, the degron is an N-degron, located at or near the N-terminus of the protein.

[0068] Provided are fusion proteins that comprise certain sequence elements or structural motifs (e.g., degron) that act as degradation signals. In some embodiments, the certain sequence elements or structural motifs are C-degron peptides.

[0069] Exemplary' C-degron peptides that can be employed in any of the provided embodiments include those described in, for example, Gilon et al. (1998) EMBO J. 17: 2759- 2766; Maurer et al., (2016) G3 (Bethesda). 6: 1853-1866; Bence et al., (2001) Science, 292(5521), 1552-1555; Leto et al., (2019) Mol Cell, 73(2), 377-389 e311 ; Stefanovic-Barrett et al., (2018) EMBO Rep, 19(5):201745603; Varshavsky et al., (2019) PNAS, 116 (2): 358-366; and Timms et al., (2020) Biochemical Society Transactions 48: 1557-1567; and Yeh et al., (2021) The EMBO Journal 40: el05846.

[0070] In some embodiments, the C-degron peptide comprises a hydrophobic region. In some embodiments, the C-degron peptide comprises an a-helical region.

[0071] In some embodiments, the C-degron peptide is a degron. In some embodiments, the C-degron peptide is selected from among CL1, CL2, CL6, CL9, CLIO, CL11, CL 12, CL 15, CL16, or CL17 (see, e.g., Gilon et al. (1998) EMBO J. 17: 2759-2766). In some aspects, an exemplary is C-degron peptide is an artificial degron named CL1. In some aspects, CL1 is targeted by the human ortholog of DoalO, a Membrane-associated RING-CH-type finger protein 6 (MARCH6; also called MARCHF6), among other E3 ligases (Bence et al., (2001) Science, 292(5521), 1552-1555; Leto et al., (2019) Mol Cell, 73(2), 377-389 e311; Stefanovic- Barrett et al., (2018) EMBO Rep, 19(5): 201745603). In some embodiments, the C-degron peptide comprises CL 1 or a variant thereof.

[0072] In some embodiments, the C-degron peptide is selected from among CL1, HO-1, SQLE, PLIN2, DIO2, and / or lanosterol-13 a-demethylase.

[0073] In some embodiments, the C-degron peptide is selected from among 10-1, 10-6, 10- 13, 10-15, 10-21, 10-31, 10-32, 12-32, 12-33, 10-34, 10-40, 10-43, 12-86, and / or 12-98 (see, e.g, Maurer et al., (2016) G3 (Bethesda). 6: 1853-1866).

[0074] In some embodiments, methods for enhanced protein degradation by addition of a degron includes, but is not limited to attaching a C-terminal or N-terminal sequence motif to the fusion protein. In some embodiments, the degron is a C-terminal degron.

[0075] In some embodiments, the C-degron peptide is at least 2 amino acids in length. In some embodiments, the C-degron peptide is at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids in length. In some embodiments, the C-degron peptide is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids in length.

[0076] In some embodiments, the C-degron peptide is 10 amino acids in length. In some embodiments, the C-degron peptide is 11 amino acids in length. In some embodiments, the C- degron peptide is 12 amino acids in length. In some embodiments, the C-degron peptide is 13 amino acids in length. In some embodiments, the C-degron peptide is 14 amino acids in length. In some embodiments, the C-degron peptide is 15 amino acids in length. In some embodiments, the C-degron peptide is 16 amino acids in length. In some embodiments, the C-degron peptide is 17 amino acids in length. In some embodiments, the C-degron peptide is 18 amino acids in length. In some embodiments, the C-degron peptide is 19 amino acids in length. In some embodiments, the C-degron peptide is 20 amino acids in length.

[0077] In some embodiments, the degrons direct proteins for degradation via the Ubc6 and / or Ubc7 sub-pathways of the ubiquitin system. In some embodiments, the degrons contain a highly hydrophobic region.

[0078] In some embodiments, the C-degron peptide comprises an E3 ubiquitin ligase target motif. In some embodiments, the E3 ubiquitin ligase target motif comprises a target motif of DoalO, MARCHF6, CRL2, NOT4, ELOB, ELOC, DDB1, CUL2, CUL4, KLHDC1, KLHDC2, KLHDC3, KLHDC10, FEM1A, FEM1B, FEM1C, APPBP2, DCAF12, TRPC4AP, UBC6, UBC7, UBR1, UBR2, UBR4, and / or UBR5. In some embodiments, the E3 ubiquitin ligase target motif comprises a target motif of DoalO or MARCHF6.

[0079] In some embodiments, the C-degron peptide comprises an FSSL-like sequence. In some embodiments, the C-degron peptide comprises the following formula: [F,W or Y]-[S or T]-[S or T]-[I, L or V]-XX-[hydrophobic]-X-[I, L or V]-[H-bond acceptor], wherein X is any amino acid.

[0080] In some embodiments, the C-degron peptide comprises a CL1, a CL2, a CL6, a CL9, a CLIO, a CL11, a CL12, a CL15, or a CL16 sequence or a variant thereof.

[0081] In some embodiments, the C-degron peptide comprises the sequence set forth in any one of SEQ ID NOS: 1 and 39-46, a contiguous portion of any one of SEQ ID NOS: 1 and 39-46 of at least 4 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing.

[0082] In some embodiments, the C-degron peptide comprises a CL1 sequence or a variant thereof. In some embodiments, the C-degron peptide comprises the sequence set forth in SEQ ID NO: 1, a contiguous portion of SEQ ID NO: 1 of at least 4 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing. In some embodiments, the C-degron peptide comprises the sequence set forth in SEQ ID NO: 1.C. Vaccine Epitopes

[0083] In some embodiments, the fusion protein comprises a vaccine epitope. In some embodiments, the fusion protein comprises one or more vaccine epitopes.

[0084] In some aspects, the fusion proteins include multiple vaccine epitopes, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 28, 29, or 30 epitopes. In some aspects, the fusion protein comprises 2 different vaccine epitopes. In some aspects, the fusion protein compnses 3 different vaccine epitopes. In some aspects, the fusion protein comprises 4 different vaccine epitopes. In some aspects, the fusion protein comprises 5 different vaccine epitopes. In some aspects, the fusion protein comprises 6 different vaccine epitopes. In some aspects, the fusion protein comprises 7 different vaccine epitopes. In some aspects, the fusion protein comprises 8 different vaccine epitopes. In some aspects, the fusion protein comprises 9 different vaccine epitopes. In some aspects, the fusion protein comprises 10 different vaccine epitopes. In some aspects, combining sequences improves processing and presentation of MHC Class I and II epitopes.

[0085] In some embodiments, a nucleic acid encoding the fusion protein, such as a ribonucleic acid (RNA), is introduced to a subject. In some aspects, upon administration, the nucleic acid construct is taken up and translated by antigen presenting cells (APCs) and the expressed vaccine epitope is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. In some aspects, this can lead to immune responses, such as T cell- mediated immune responses to the vaccine epitope or cells expressing the vaccine epitope (e.g., cancer cells expressing the neoepitope).

[0086] In some aspects, when the fusion protein comprises multiple epitopes, each of the different vaccine epitopes are from different proteins. In some aspects, when the fusion protein comprises multiple epitopes, each of the different vaccine epitopes are from the same protein. In some aspects, when the fusion protein comprises multiple epitopes, some of the vaccine epitopes can be from the same protein, and others can be from different proteins.

[0087] In some embodiments, the vaccine epitope comprises an infectious disease vaccine epitope. In some embodiments, the vaccine epitopes are bacterial epitopes, viral epitopes, cancer epitopes, fungal epitopes, and / or infectious disease epitopes.

[0088] In some embodiments, the vaccine epitope comprises a viral vaccine epitope. In some aspects, the viral vaccine epitope comprises an antigen encoded by a vims. In some aspects, the viral vaccine epitope is from a virus that is a member of Coronaviridae. In some embodiments, the viral vaccine epitope is from an alphacoronavirus, a betacoronavirus, a deltacoronavirus, or a gammacoronavirus. In some embodiments, the virus is a human coronavirus OC43 (HCoV-OC43), human coronavirus HKU1 (HCoV-HKUl), human coronavirus 229E (HCoV-229E), human coronavirus NL63 (HCoV-NL63), Middle East respiratory syndrome-related coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In some embodiments, the virus is SARS-CoV-2. In some aspects, the viral vaccine epitope is from a SARS-CoV-2 vims.

[0089] In some embodiments, the vaccine epitopes are infectious disease epitopes. In some embodiments, the epitope is a disease-associated epitope, i.e., an epitope that arises from presentation of a viral or bacterial antigen, or part of a bacterial or viruses such as a protein or peptide expressed in a bacterial or vimses which may be derived from the cytoplasm, the cell surface or the cell nucleus, in particular those which primarily occur intracellularly or as surfaceantigens of bacterial or viruses. For example, infectious disease epitopes include the SARS- CoV-2 spike glycoprotein.

[0090] In some embodiments, the vaccine epitope comprises a cancer epitope. In some embodiments, the cancer epitope is a cancer neoantigen epitope.

[0091] In some embodiments, the step of identifying infectious disease-associated antigens and epitopes or identifying sequence differences involves using next generation sequencing (NGS). In some embodiments, the step of identifying infectious disease-associated epitopes or identifying sequence differences comprises sequencing genomic DNA and / or RNA of the virus or bacteria sample.

[0092] In some embodiments, the vaccine antigen comprises a cancer antigen. In some aspects, the cancer antigen is a tumor-associated antigens (TAAs) or a tumor-specific antigens (TSAs). Exemplary cancer antigens, TAAs or TSAs include, but are not limited to, those described in, for example, Liu et al., Journal of Hematology & Oncology 15:28 (2022); Buonaguro et al., Vaccines (Basel). 2020 Dec; 8(4): 615; and Zhao et al., Vaccines (Basel). 2021 Feb; 9(2): 85.

[0093] In some embodiments, the vaccine epitopes are cancer epitopes. In some embodiments, the epitope is a tumor-associated epitope, i.e., an epitope that arises from presentation of a tumor antigen, or part of a tumor cell such as a protein or peptide expressed in a tumor cell which may be derived from the cytoplasm, the cell surface or the cell nucleus, in particular those which primarily occur intracellularly or as surface antigens of tumor cells. In some embodiments, a tumor-associated epitope preferably comprises any epitope which is expressed in and optionally characteristic with respect to type and / or expression level for tumors or cancers as well as for tumor or cancer cells.

[0094] In some embodiments, the cancer specific mutations include mutations present in one or more cancer cells of a patient. In some aspects, the vaccine epitope is a cancer neoantigen epitope (also called neoepitope or cancer neoepitope). In some embodiments, the cancer neoepitope is a new epitope, e.g., a newly arising peptide sequence, that arises in cancer cells as a result of mutations in the cancer cell. In some aspects, cancer neoepitopes of the provided embodiments can be selected by identifying of a number of mutations which provides a sufficient number of neoepitopes to be included in a fusion protein. A “cancer mutation”relates to a sequence difference between the nucleic acid contained in a cancer cell and the nucleic acid contained in a normal cell.

[0095] In some cases, the cancer mutations are non-synonymous mutations, in some cases non-synonymous mutations of proteins expressed in a tumor or cancer cell. In some embodiments, cancer specific somatic mutations or sequence differences are determined in the genome, in some cases the entire genome, of a tumor specimen. In some aspects, neoepitopes can be identified from the cancer mutation signature of the genome, in some cases the entire genome of one or more cancer cells. In some embodiments, identifying cancer specific somatic mutations in a tumor specimen of a cancer patient comprises identifying the genome-wide cancer mutation profile. In some embodiments, cancer specific somatic mutations or sequence differences are determined in the exome, in some cases the entire exome, of a tumor specimen. In some aspects, neoepitopes can be identified from the cancer mutation signature of the exome, in some cases the entire exome of one or more cancer cells. In some embodiments, identifying cancer specific somatic mutations in a tumor specimen of a cancer patient comprises identifying the exome-wide cancer mutation profile. In some embodiments, cancer specific somatic mutations or sequence differences are determined in the trans criptome, in some cases the entire trans criptome, of a tumor specimen. In some aspects, neoepitopes can be identified from the cancer mutation signature of the trans criptome, in some cases the entire transcriptome of one or more cancer cells. In some embodiments, identifying cancer specific somatic mutations in a tumor specimen of a cancer patient comprises identifying the transcriptome-wide cancer mutation profile. In some embodiments, identifying cancer specific somatic mutations or identifying sequence differences comprises single cell sequencing of one or more, in some cases 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or even more cancer cells. In some aspects, neoepitopes can be identified from a cancer mutation signature of said one or more cancer cells.

[0096] In some embodiments, the cancer cells from which cancer neoepitopes can be identified include circulating tumor cells. The cancer cells such as the circulating tumor cells may be isolated prior to single cell sequencing. In some embodiments, identifying cancer specific somatic mutations or identify ing sequence differences involves using next generation sequencing (NGS). In some embodiments, identifying cancer specific somatic mutations oridentifying sequence differences comprises sequencing genomic DNA and / or RNA of the tumor specimen.

[0097] To reveal cancer specific somatic mutations or sequence differences, and to determine cancer neoepitopes to include in the fusion protein, the sequence information obtained from the tumor specimen is compared with a reference such as sequence information obtained from sequencing nucleic acid such as DNA or RNA of normal non-cancerous cells such as germhne cells which may either be obtained from the patient or a different individual. In some embodiments, normal genomic germline DNA is obtained from peripheral blood mononuclear cells (PBMCs)

[0098] In some aspects, the fusion proteins comprise neoepitopes (i.e., tumor-associated antigens (TAAs) that are specifically expressed in the patient’s cancer) identified as having potential immunostimulatory activities.

[0099] In some embodiments, the fusion protein comprises a cancer neoantigen epitopes selected from among one or more of: MEI, M26, Gludl, Mtchl, M18, Steap2, and E2f8.

[0100] In some aspects, the vaccine epitope independently comprises a sequence selected from the sequence set forth in SEQ ID NOS:2-8, a contiguous portion of a sequence selected from the sequence set forth in SEQ ID NOS:2-8 of at least 8 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing.

[0101] In some embodiments, the fusion protein comprises the neoepitope AHI. In some embodiments, the AHI neoepitope comprises the sequence set forth in SEQ ID NO:2, a contiguous portion of SEQ ID NO:2 of at least 8 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing. In some embodiments, the AHI neoepitope comprises the sequence set forth in SEQ ID NO:2.

[0102] In some embodiments, the fusion protein comprises the neoepitope MEI. In some embodiments, the MEI neoepitope comprises the sequence set forth in SEQ ID NO:3, a contiguous portion of SEQ ID NO:3 of at least 8 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing. In some embodiments, the MEI neoepitope comprises the sequence set forth in SEQ ID NO:3.

[0103] In some embodiments, the fusion protein comprises the neoepitope E2f8. In some embodiments, the E2f8 neoepitope comprises the sequence set forth in SEQ ID NO:4, a contiguous portion of SEQ ID NO:4 of at least 8 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing. In some embodiments, the E2f8 neoepitope comprises the sequence set forth in SEQ ID NO:4.

[0104] In some embodiments, the fusion protein comprises the neoepitope Gludl. In some embodiments, the Gludl neoepitope comprises the sequence set forth in SEQ ID NO:5, a contiguous portion of SEQ ID NO:5 of at least 8 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing. In some embodiments, the Gludl neoepitope comprises the sequence set forth in SEQ ID NO:5.

[0105] In some embodiments, the fusion protein comprises the neoepitope Mtchl. In some embodiments, the Mtchl neoepitope comprises the sequence set forth in SEQ ID NO:6, a contiguous portion of SEQ ID NO:6 of at least 8 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing. In some embodiments, the Mtchl neoepitope comprises the sequence set forth in SEQ ID NO: 6.

[0106] In some embodiments, the fusion protein comprises the neoepitope Ml 8. In some embodiments, the Ml 8 neoepitope comprises the sequence set forth in SEQ ID NO:7, a contiguous portion of SEQ ID NO:7 of at least 8 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing. In some embodiments, the Ml 8 neoepitope comprises the sequence set forth in SEQ ID NO:7.

[0107] In some embodiments, the fusion protein comprises the neoepitope Steap2. In some embodiments, the Steap2 neoepitope comprises the sequence set forth in SEQ ID NO: 8, a contiguous portion of SEQ ID NO: 8 of at least 8 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing. In some embodiments, the Steap2 neoepitope comprises the sequence set forth in SEQ ID NO: 8.

[0108] In some embodiments, the vaccine epitope is an epitope of an autoantigen or an antigen associated with an autoimmune disease. Autoimmune diseases are broadly classified into two categories, organ-specific and systemic diseases. The precise etiology of systemic auto-immune diseases is not identified. In contrast, organ-specific auto-immune diseases are related to a specific immune response including B and T cells, which targets the organ and thereby induces and maintains a chronic state of local inflammation. Examples of organspecific auto-immune diseases include type 1 diabetes, myasthenia gravis, thyroiditis and multiple sclerosis. In some aspects, in these conditions, a single or a small number of autoantigens have been identified, including insulin, the acetylcholine muscle receptor, thyroid peroxidase and major basic protein, respectively. In some embodiments, the vaccine epitope includes an epitope from insulin, the acetylcholine muscle receptor, thyroid peroxidase and / or major basic protein. Autoimmune diseases or disorders include diseases that result from an aberrant immune response of an organism against its own cells and tissues due to a failure of the organism to recognize its own constituent parts (down to the sub-molecular level) as “self’.

[0109] In some embodiments, the fusion proteins also includes an MHC trafficking signal. In some embodiments, the fusion protein comprises an MHC class I trafficking signal (MITD). In some embodiments, the MITD comprises the sequence set forth in SEQ ID NO: 16, a contiguous portion of SEQ ID NO: 16 of at least 8 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing. In some embodiments, the MITD comprises the sequence set forth in SEQ ID NO:16.

[0110] In some embodiments, the fusion proteins include a signal sequence, and / or a domain to facilitate epitope expression.D. Linkers[OHl] In some embodiments, the fusion protein further comprises one or more peptide linkers. In some embodiments, the one or more peptide linkers are located between different vaccine epitopes. In some embodiments, the fusion protein comprises one or more peptide linkers. In some cases, peptide linkers are used between two or more vaccine epitope sequences, between a vaccine epitope sequence and the C-degron peptide, or between a translation initiation element or signal sequence and a vaccine epitope sequence.

[0112] In some embodiments, the fusion protein contains multiple linkers. In some embodiments, the fusion protein comprises multiple vaccine epitopes, such as 5-20 vaccine epitopes, and each epitope is separated by a linker sequence. In some embodiments, two or more linkers encoded by the fusion protein comprise different sequences. In some embodiments, the fusion protein encodes multiple linkers, all of which share the same amino acid sequence.

[0113] In some aspects, a variety of peptide linkers are known. In some embodiments, the linker is a flexible linker. In some embodiments, the linker comprises G, S, A, and / or T residues. In some embodiments, the linker consists of glycine and serine residues. In some embodiments, the linker is between 5 and 20 amino acids in length, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length. In some embodiments, the linker comprises the sequence GGGGSGGGGS (SEQ ID NO: 14).

[0114] In some embodiments, the linker of the fusion protein is a natural linker. In some aspects, a “natural linker” refers to sequences that naturally occur near the vaccine epitope, such as 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous amino acids that occur adjacent to the vaccine epitope sequence in the endogenous protein. In some aspects, a natural linker comprises 10, 11, 12, 13, 14, or 15 contiguous amino acids that naturally occur adjacent to the vaccine epitope sequence in the N-terminal direction. In some aspects, a natural linker comprises 10, 11, 12, 13, 14, or 15 contiguous amino acids that naturally occur adjacent to the vaccine epitope sequence in the C-terminal direction. In some aspects, a natural linker comprises 12 contiguous amino acids that naturally occur adjacent to the vaccine epitope sequence in the N-terminal direction. In some aspects, a natural linker comprises 12 contiguous amino acids that naturally occur adjacent to the vaccine epitope sequence in the C-terminal direction.

[0115] In some embodiments, the one or more peptide linkers independently comprises a natural linker comprising 5 or more adjacent amino acids that naturally occur in the N- terminal or C-terminal of the vaccine epitope. In some embodiments, the one or more peptide linkers independently comprises a natural linker comprising 8, 9, 10, 11, 12, 13, 14, 15, or 16 or more adjacent amino acids that naturally occur in the N- terminal or C-termmal of the vaccine epitope. In some embodiments, the one or more peptide linkers independently comprises the sequence set forth in any one of SEQ ID NOS:28-38, a contiguous portion of any one of SEQID NOS:28-38 of at least 8 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing.IL NUCLEIC ACID CONSTRUCTS FOR VACCINE EPITOPE PRESENTATION

[0116] Provided herein is a nucleic acid construct encoding any of the fusion proteins described herein.

[0117] In some embodiments, the nucleic acid construct is RNA and / or DNA. In some embodiments, the nucleic acid construct is RNA. In some embodiments, the nucleic acid construct is circular RNA. In some embodiments, the nucleic acid construct is linear RNA. In some embodiments, the nucleic acid construct is DNA.A. Nucleic Acid Constructs

[0118] In some embodiments, the nucleic acid construct is a linear RNA molecule. In some embodiments, the nucleic acid construct is a messenger RNA (mRNA) molecule. In some embodiments, the nucleic acid construct is a capped mRNA.

[0119] In some embodiments, the nucleic acid comprises a cleaved linear RNA comprising a hydroxyl group at the 5' terminus, and a 2',3'-cyclic phosphate at the 3' terminus.

[0120] In some embodiments, the linear RNA is at least 600 nt, at least 1000 nt, or at least 1200 nt in length. In some embodiments, the linear RNA is less than 2000 nt in length. In some embodiments, the linear RNA is at least 600 nt but less than 2000 nt in length, at least 1000 nt but less than 2000 nt in length, at least 1200 nt but less than 2000 nt in length, at least 1400 nt but less than 2000 nt in length, at least 600 nt but less than 1400 nt in length, or at least 600 nt but less than 2000 nt in length.

[0121] In some embodiments, the nucleic acid construct is a circular RNA molecule. CircRNA is a covalently closed continuous loop of single-stranded RNA. CircRNA can be divided into four categories including exonic CircRNA (ecircRNA), circular intronic RNA (ciRNA), exon-intron circRNA (ElciRNA), and intergenic circRNA.

[0122] For delivery of RNA-encoded genes into cells and expression of the gene products, the stability of RNA is one of the critical factors in enhancing the gene product expression. Strategies have been developed to overcome the lack of stability and potential immunogenicity of linear mRNAs. Developed approaches include using untranslated regions (UTRs) such as those present in the native beta-globin mRNA, using methylguanosine cap analogs to protectthe mRNA from de-capping enzymes, nucleoside modification, and codon optimization. However, only modest improvements have been observed.

[0123] The configuration of circRNA results in several advantages compared to linear mRNA, including resistance to exonuclease-mediated degradation, increased stability, extended half-life, increased protein expression, and reduced immunogenicity (Chen, RNA Biol, 12(4): 381 -388 (2015); Wesselhoeft et al., Nat Commun, 9(1):2629 (2018)). circRNA generally has a longer half-life compared to their linear mRNA counterparts (Wesselhoeft et al., Nat Commun, 9(1):2629 (2018)). Accordingly, circRNA improves protein expression (e.g., of the encoded gene product) over its lifetime compared to linear mRNAs. CircRNA can be synthesized in vitro by chemical, enzymatic, and ribozymatic approaches. One approach, using permuted intron-exon (PIE) splicing to result in RNA circularization, has been developed to express gene products from circRNA. PIE splicing systems based on Group I introns that are naturally found in the rRNA, tRNA, and mRNA genes of bacteria and non-metazoan eukaryotes can produce circRNA by self-splicing.

[0124] In some embodiments, the circular RNA is at least 600 nt, at least 1000 nt, or at least 1200 nt in length. In some embodiments, the circular RNA is less than 2000 nt in length. In some embodiments, the circular RNA is at least 600 nt but less than 2000 nt in length, at least 1000 nt but less than 2000 nt in length, at least 1200 nt but less than 2000 nt in length, at least 1400 nt but less than 2000 nt in length, at least 600 nt but less than 1400 nt in length, or at least 600 nt but less than 2000 nt in length.

[0125] In some embodiments, the nucleic acid construct is a DNA molecule. In some embodiments, the nucleic acid construct is a naked DNA molecule. In some embodiments, the nucleic acid construct is a double-stranded DNA molecule. In some embodiments, the nucleic acid construct is a single-stranded DNA molecule. In some embodiments, the nucleic acid construct is a modified DNA molecule. In some embodiments, the nucleic acid construct is modified to enhance its stability. In some embodiments, the nucleic acid construct is a closed- ended DNA molecule. In some embodiments, the nucleic acid construct is a naked closed-ended DNA molecule.

[0126] In some embodiments, the DNA is at least 600 nt, at least 1000 nt, or at least 1200 nt in length. In some embodiments, the DNA is less than 2000 nt in length. In some embodiments, the DNA is at least 600 nt but less than 2000 nt in length, at least 1000 nt but less than 2000 ntin length, at least 1200 nt but less than 2000 nt in length, at least 1400 nt but less than 2000 nt in length, at least 600 nt but less than 1400 nt in length, or at least 600 nt but less than 2000 nt in length.B. Regulatory Sequences and Translation Initiation Elements

[0127] In some embodiments, the nucleic acid construct further comprises one or more elements that facilitates the expression and / or processing of the encoded fusion protein.

[0128] In some embodiments, the nucleic acid construct further comprises a translation initiation element. In some embodiments, the translation initiation element is an internal ribosome entry site (IRES) or a Translation Initiator of Short 5' UTR (TISU) element. In some embodiments, the translation initiation element is or comprises an internal ribosome entry site (IRES). In some embodiments, the IRES comprises a Coxsackievirus B3 internal ribosome entry site (CVB3 IRES) sequence. In some embodiments, the IRES sequence comprises a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to the sequence set forth in SEQ ID NO:27. In some embodiments, the IRES sequence comprises the sequence set forth in SEQ ID NO:27.

[0129] In some embodiments, the translation initiation element comprises a Translation Initiator of Short 5' UTR (TISU) element. TISU is a regulator}' element that controls both transcription and translation initiation of genes with basic cellular functions.

[0130] In some cases, when the insert sequence contains sequences encoding multiple exogenous molecules, a multicistronic element can be used, typically placed between the different coding sequences, to express multiple polypeptide gene products. Exemplary multicistronic elements include 2A elements that result in the separation between the end of the 2A sequence and the next peptide downstream (see, e.g., de Felipe, Genetic Vaccines and Ther. 2: 13 (2004) and de Felipe et al. Traffic 5:616-626 (2004)).

[0131] In some embodiments, the nucleic acid constructs provided herein comprises a poly adenine cytosine (poly AC) sequence. In some aspects, the poly AC sequence can be located 3' of the coding sequence for the exogenous molecule.III. VACCINATION, THERAPEUTIC AND PROPHYLACTIC METHODS ANDUSES

[0132] Also provided are methods of administering and uses, such as prophylactic and therapeutic uses, of the fusion proteins or nucleic acid constructs encoding the fusion proteins comprising vaccine epitopes and C-degron peptide, or compositions comprising the fusion protein or nucleic acid constructs. In some embodiments, the fusion protein, nucleic acid construct, and / or composition is administered in an effective amount to effect treatment of the disease or disorder. Uses include uses of the fusion protein, nucleic acid construct, and / or composition in such methods and treatments, and in the preparation of a medicament in order to carry out such therapeutic or prophylactic methods. In some embodiments, the methods are carried out by administering the fusion protein, nucleic acid construct, and / or composition, to the subject having, having had, or suspected of having the disease or condition. In some embodiments, the methods thereby treat the disease or condition or disorder in the subject. In some embodiments, the disease condition or disorder in the subject is cancer. In some embodiments, the disease condition or disorder in the subject is an infectious disease, optionally a viral infection. In some embodiments, the disease condition or disorder in the subject is an autoimmune disease.

[0133] In some embodiments, administration of the fusion protein, nucleic acid construct or composition induces an immune response. In some embodiments, administration of the fusion protein, nucleic acid construct or composition induces an immune response comprising a CD4+ T cell response, CD8+ T cell response and / or antibody response. In some embodiments, administration of the fusion protein, nucleic acid construct or composition induces an immune response comprising a CD4+ T cell response and / or CD8+ T cell response. In some aspects, provided are fusion proteins that can enhance the efficiency of vaccine epitope presentation. In some aspects, the provided fusion protein comprise one or more vaccine epitopes, in some cases multiple vaccine epitopes, fused with a C-degron peptide, such as a MARCHF6 substrate peptide, e.g., CL1.

[0134] In some embodiments, the fusion protein results in induction of an immune response such as a CD4+ T cell response, CD8+ T cell response and / or antibody response, specific for the vaccine epitopes.

[0135] In some aspects, as described herein, the exemplar.' C-degron CL1 is an effective cleavage motif to generate both CD4 and CD8+T cell-specific response. In some aspects, CL1 can be fused to a variety of vaccine epitopes, including cancer neoantigen epitopes, tumor- associated antigen (TAA) epitopes, and viral oncogene epitopes, for stimulating epitopespecific T cells.

[0136] In some aspects, fusion proteins comprising C-degrons, such as CL1, can also be used for autoantigen vaccines to control autoimmune diseases by promoting autoantigens- specific regulatory T cells to induce immune tolerance.

[0137] In some aspects, fusion proteins comprising C-degrons, such as CL1, can also be used to develop preventive vaccines against infectious disease agents, such as viruses, with frequent mutations. As T cells can recognize the linear peptides that have slightly different amino acid sequences with similar binding affinity, thus can be effective against viruses that mutate frequently and encode minor variations of the epitope. Because antibodies recognize the three-dimensional structure of viral epitopes, they may not recognize the antigen if a mutation changes the structure of the antigen. In some aspects, vaccine approaches that primarily target T cells and can elicit a robust T cell response are more efficient in controlling viruses that have more frequent mutants than antibody-specific vaccines.

[0138] In some aspects, the provided embodiments can be used to treat, prevent, reduce the severity of and / or vaccinate against a disease or disorder.

[0139] In some embodiments, the disease or disorder is an infectious disease. In some embodiments, the disease or disorder is a viral infection.

[0140] In some embodiments, the disease or disorder is a cancer or a tumor. Among the diseases or conditions that can be treated include, but are not limited to, B cell leukemia, lymphoma, B cell chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), Burkitt's Lymphoma, mantle cell lymphoma (MCL), non-small cell lung cancer (NSCLC), neuroblastoma, renal cell carcinoma, colon cancer, colorectal cancer, breast cancer, epithelial squamous cell cancer, melanoma, myeloma, stomach cancer, brain cancer, lung cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, prostate cancer, testicular cancer, thyroid cancer, uterine cancer, adrenal cancer and head and neck cancer. In some aspects, the cancer is melanoma, non-small cell lung cancer, bladder cancer, colorectal cancer, triple negative breast cancer, renal cancer, and head and neckcancer. In some embodiments, the cancer is locally advanced or metastatic melanoma, nonsmall cell lung cancer, bladder cancer, colorectal cancer, triple negative breast cancer, renal cancer, or head and neck cancer.

[0141] In some embodiments, the cancer is colorectal carcinoma. In some embodiments, the cancer is carcinoma. In some embodiments, the carcinoma is metastatic or unresectable locally advanced melanoma. In some embodiments, the carcinoma is stage IV carcinoma. In some embodiments, the carcinoma is stage IIIC or stage HID carcinoma. In some embodiments, the carcinoma is unresectable or metastatic carcinoma.

[0142] In some embodiments, the disease or disorder is an autoimmune disease. In some embodiments, the autoimmune disease or disorder includes type 1 diabetes, myasthenia gravis, thyroiditis and multiple sclerosis.A. Compositions and Delivery Vectors

[0143] Provided herein are compositions comprising the fusion proteins or nucleic acid constructs encoding the fusion proteins comprising vaccine epitopes. In some aspects, the fusion protein or nucleic acid construct is administered to a subject, such as a subject with a disease or condition, or to prevent or reduce the severity of a disease or condition. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the composition comprises a pharmaceutically acceptable excipient.

[0144] In some embodiments, any of fusion proteins or nucleic acid constructs described herein or compositions comprising the same, are compatible with viral or non-viral vector delivery methods. In some aspects, the composition involves introduction of a nucleic acid construct encoding the fusion protein or other component for introduction into a cell in a subject. Exemplary non-viral vector delivery methods include physical or chemical means of delivery. For example, a physical non-viral delivery method includes electroporation. Exemplary chemical non-viral delivery vectors include nanoparticles, fat molecules (e.g., lipids) or polymers. In some embodiments, the any of the fusion proteins, nucleic acid constructs described herein or compositions comprising the same, are delivered via nanoparticle. In some embodiments, the nanoparticle is a lipid nanoparticle (LNP).

[0145] In some embodiments, the composition comprises a LNP. Any known or commonly used lipid nanoparticle compositions can be used to administer the provided fusion proteins and / or nucleic acid constructs to a subject.

[0146] In some contexts, LNPs are nanoparticles comprising lipids which can act as pharmaceutical drug delivery systems, and in some cases as part of the pharmaceutical drug. In some aspects, LNPs are commonly used non-viral delivery system for therapeutics and vaccines. LNPs are typically spherical with the core of the LNP or a layer being lipophilic while the outside surface is often hydrophilic, allowing emulsions of the LNPs to be formed within an aqueous solution. In some contexts, the core can be lipophilic to allow for solubilization and delivery of lipophilic molecules as a payload. In some contexts, the LNP can include a bilayer, allowing the core to by hydrophilic, similar to the outside surface, allowing solubilization and deliver of hydrophilic molecules as a payload. In some aspects, LNPs are often used with emulsifiers, which may include triglycerides, diglycerides, monoglycerides, fatty acids, steroids, and / or waxes, which can help to stabilize the LNPs while also preventing particle agglomeration. LNPs can be used to deliver a wide range of payloads (i.e., cargo) to cells, including fusion proteins or nucleic acid constructs.

[0147] In some embodiments, the nanoparticles are cationic nanoparticles. In some embodiments, the LNP is comprises lipids which are amphiphilic. In some embodiments, the lipids may include l,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 1,2- dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1 ,2-dioleoyl-3-trimethylammonium- propane (DOTAP), dimethyldioctadecylammonium bromide (DDAB), 2,3-dioleyloxy-N-[2- (sperminecarboxamido)ethyl]-N,N-dimethyl-l-propanaminium trifluoroacetate (DOSPA), and / or 2-(((((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)- 2,3,4,7,8,9,10,l l,12,13,14,15,16,17-tetradecahydro-lH-cyclopenta[a]phenanthren-3- yl)oxy)carbonyl)amino)-N,N-bis(2-hydroxy ethyl)-N-methylethan- 1 -aminium bromide (BHEM- Cholesterol). In some aspects, the nanoparticles comprise DOTMA and DOPE.

[0148] In some embodiments, the lipids may include analogues to any of the previously mentioned lipids. In some embodiments, the LNP includes a helper lipid, which may respond to pH changes during subcellular trafficking in endosomes. In some embodiments, the helper lipid may have an amino head group, phosphoethanolamine, and unsaturated oleoyl lipid chains. In some embodiments, the lipids may further include cholesterol. In some embodiments, DOTMAis a cationic lipid that helps in gene transfer. In some embodiments, is a quaternary ammonium lipid. In some embodiments, DOTMA induces a positive charge on the surface which promotes efficient interactions between the nanoparticle and the cell surface.

[0149] In some embodiments, the nanoparticles comprise a nucleic acid construct as a payload. In some aspects, a nucleic acid is delivered via the nanoparticles. In some embodiments, the nanoparticle aids in delivery of the nucleic acid. In some embodiments, the nanoparticle leads to delivery of the nucleic acid to a cell. In some embodiments, the nanoparticle delivers the nucleic acid intracellularly. In some embodiments, the nanoparticle overcomes endosomal barriers for intracellular delivery of the nucleic acid. In some embodiments, the nanoparticle fuses with the cell membrane, leading to intracellular delivery of the nucleic acid.

[0150] In some embodiments the LNP is a lipoplex (LPX) nanoparticle. In some aspects, LPX are cationic lipid-nucleic acid complexes, are formed by the interaction of anionic nucleic acids binding to positively charged lipid vesicles. In some embodiments, the LNP is an LPX nanoparticle comprising DOTMA and DOPE. In some aspects, the nanoparticles are LPX nanoparticles comprising DOTMA, DOPE, and a nucleic acid construct, such as an RNA construct. In some aspects, the nucleic acid to be delivered using the nanoparticles include sequences encoding one or more vaccine epitopes.

[0151] In some embodiments, the nanoparticles can aid in treating cancer. In some embodiments, the cationic nanoparticles induce antigen specific CD4+ T cell proliferation thereby reducing cancer. In some embodiments, the CD4+ T cell proliferation is due to delivery of the nucleic acid construct to a target cell.

[0152] In some embodiments, composition comprises a lipoplex (LPX). In some embodiments, the nucleic acid construct is formulated in a LPX nanoparticle or liposome. In some embodiments, a LPX nanoparticle formulation is used for delivery of any of the provided fusion protein or nucleic acid constructs. In some embodiments, a LPX nanoparticle formulation for the RNA (RNA-LPX) is used for delivery of any of the provided RNA constructs. In some aspects, the lipid nanoparticle is administered intravenously (IV). In some embodiments, a LPX nanoparticle formulation comprises cationic lipid l,2-di-O-octadecenyl-3- trimethylammonium propane (DOTMA) and the phospholipid l,2-dioleoyl-sn-glycero-3- phosphoethanolamine (DOPE). In some aspects, the DOTMA / DOPE liposomal component canbe used for IV delivery and targeting of antigen-presenting cells in the spleen and other lymphoid organs.

[0153] In some embodiments, the fusion proteins, nucleic acid constructs, or compositions comprising the same, can be administered by any suitable means, for example, by injection, e.g., intravenous or subcutaneous injections, intraocular injection, periocular injection, subretinal injection, intravitreal injection, trans-septal injection, subscleral injection, intrachoroidal injection, intracameral injection, subconjectval injection, subconjuntival injection, sub-Tenon's injection, retrobulbar injection, peribulbar injection, or posterior juxtascleral delivery. In some embodiments, they are administered by parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration. In some embodiments, the fusion protein or nucleic acid construct is administered (e.g., in a lipoplex particle or liposome) intravenously, intramuscularly, subcutaneously, topically, orally, trans dermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, intracranial, intrathoracic, or subcutaneous administration. Dosing and administration may depend in part on whether the administration is brief or chronic. Various dosing schedules include but are not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion. In some embodiments, the fusion proteins, nucleic acid constructs, or compositions comprising the same are administered intravenously.

[0154] In some embodiments, the fusion protein, nucleic acid construct and / or composition is administered in the presence of an adjuvant. In some embodiments, the fusion protein, nucleic acid construct and / or composition can be administered by repeat administration of the peptide a plurality of times. In some embodiments, repeated administration is with a low dose of peptide. In some embodiments, the repeat administration of the fusion protein, nucleic acid construct and / or composition occurs over an extended time period, such as for up to three days, four days, five days, six days, one week, two weeks, three weeks or a month. In some embodiments, the fusion protein, nucleic acid construct and / or composition can be administered in a high dose amount. In some embodiments, one or more administration modes, schedules or frequency of administration are employed.

[0155] In some aspects, the fusion proteins or nucleic acid constructs in the composition are engineered to promote expression of epitopes in the antigen presenting cell. Other methods that can be used to deliver nucleic acid constructs to the subject include viral, e.g., retroviral or lentiviral, transduction, transposons, and electroporation.

[0156] In some embodiments, nucleic acid constructs are transferred into cells using recombinant infectious virus particles, such as, e g., vectors derived from simian vims 40 (SV40), adenoviruses, adeno-associated vims (AAV). In some embodiments, nucleic acid constmcts are transferred into T cells using recombinant lentiviral vectors or retroviral vectors, such as gamma-retroviral vectors.

[0157] Pharmaceutically acceptable excipients can also include solvents, bulking agents, buffering agents, tonicity adjusting agents, and preservatives. In some embodiments, the compositions comprise an excipient that functions as one or more of a solvent, a bulking agent, a buffering agent, and atonicity' adjusting agent (e.g., sodium chloride in saline may serve as both an aqueous vehicle and a tonicity adjusting agent).B. Vaccination Methods and Prophylactic Methods

[0158] Provided herein are methods of administering and uses, such as in prophylactic methods and / or vaccination methods, of the provided fusion proteins, nucleic acid constmcts and / or compositions. Also provided are methods of vaccinating a subject that involves administering the provided fusion proteins, nucleic acid constructs and / or compositions provided herein. Also provided are methods of enhancing vaccine epitope presentation to elicit an immune response that involves administering the provided fusion proteins, nucleic acid constructs and / or compositions. In some aspects any of the provided methods and uses, the provided fusion proteins, nucleic acid constmcts and / or compositions are administered to a subject for vaccination and / or to prevent, delay the development of or progression of, or reduce the severity of a disease or condition.

[0159] In some embodiments, the fusion proteins, nucleic acid constmcts and / or compositions induce an increased immune response to the vaccine epitope compared to a subject that without the administration of the fusion protein, nucleic acid constmct and / or composition. In some embodiments, the fusion proteins or nucleic acid constructs encoding the vaccine epitopes and C-degron peptide or compositions induce an immune response comprisinga CD4+ T cell response, CD8+ T cell response and / or antibody response. In some embodiments, the fusion proteins, nucleic acid constructs and / or compositions prevents or reduces the severity of a disease or disorder associated with the vaccine epitope in the subject.

[0160] In some embodiments, the fusion proteins, nucleic acid constructs and / or compositions is administered to a subject for vaccinating the subject against a disease or disorder. In some aspects, one or more vaccines may be administered to a subject, e.g., subject is administered one vaccine with a combination of vaccine epitopes and also administered a separate vaccine with a different combination of vaccine epitopes

[0161] In some embodiments, the vaccine is administered such that it is delivered to the spleen. For example, the vaccine can be administered such that one or more epitopes (e.g., neoepitopes) are delivered to antigen presenting cells, for example, in the spleen.

[0162] In some embodiments, an immune response to the vaccine epitope is increased compared to a subject without expression of the fusion protein. In some embodiments, the immune response comprises CD4+ T cell response, CD8+ T cell response and / or antibody response. In some embodiments, the immune response comprises CD4+ T cell response or CD8+ T cell response.C. Therapeutic Methods

[0163] Also provided are methods of administering and uses, such as therapeutic uses, of the fusion proteins or nucleic acid constructs expressing the vaccine epitopes and C-degron peptide or compositions comprising the same.

[0164] In some embodiments, the provided fusion proteins, nucleic acid constructs and / or compositions are employed in a method of treatment for a subject having a disease or disorder. In some aspects, the methods and uses can be employed to treat, reduce the symptoms of, or ameliorate the disease or condition.

[0165] In some embodiments of the methods, a fusion protein, nucleic acid construct and / or composition is administered in a way that enhances the potential for an immune response, such as an immune response against the disease or disorder or particular target cells involved in the disease or disorder. In some aspects, this enhancement is by the induction of epitope-specific priming to particular target proteins or cells.D. Combination Therapy

[0166] Also provided are methods of administering and uses, such as in combination therapy, of the fusion proteins or nucleic acid constructs encoding the fusion protein, or compositions comprising the same.

[0167] In some embodiments, the fusion proteins or nucleic acid constructs encoding the fusion proteins, nucleic acid constructs, or compositions is administered in an effective amount in combination with an additional therapy to effect treatment of the disease or disorder. Such methods and uses include therapeutic methods and use, for example, involving administration of the fusion proteins, nucleic acid constructs, or compositions, to a subject having a disease, condition, or disorder expressing or associated with cancer or autoimmune disease. In some embodiments, the methods are carried out by administering the fusion proteins or nucleic acid constructs encoding the fusion protein, or compositions in combination with an additional therapy, to the subject having, having had, or suspected of having the disease or condition. In some embodiments, the methods thereby treat the disease or condition or disorder in the subject.

[0168] In some embodiments, the additional agent for combination treatment or combination therapy enhances, boosts and / or promotes the efficacy and / or safety of the therapeutic effect of the fusion proteins, nucleic acid constructs, or compositions. In some embodiments, the additional agent can treat the same disease, condition or a comorbidity.

[0169] In some embodiments, the additional therapeutic agent is an immune checkpoint inhibitor. In some embodiments, the additional therapeutic agent is PD-1 axis binding antagonist.

[0170] In some aspects, a checkpoint inhibitor targets at least one immune checkpoint protein to alter the regulation of an immune response. Immune checkpoint proteins include, e g., CTLA-4, PD-L1, PD-1, PD-L2, VISTA, B7-H2, B7-H3, B7-H4, B7-H6, 2B4, ICOS, HVEM, CEACAM, LAIR1, CD80, CD86, CD276, VTCN1, MHC class I, MHC class II, GALS, adenosine, TGFR, CSF1R, MICA / B, arginase, CD160, gp49B, PIR-B, KIR family receptors, TIM-1, TIM-3, TIM-4, LAG-3, BTLA, SIRPalpha (CD47), CD48, 2B4 (CD244), B7.1, B7.2, ILT-2, ILT-4, TIGIT, LAG-3, BTLA, IDO, 0X40, and A2aR. In some embodiments, molecules involved in regulating immune checkpoints include, but are not limited to: PD-1 (CD279), PD-L1 (B7-H1, CD274), PD-L2 (B7-CD, CD273), CTLA-4(CD152), HVEM, BTLA (CD272), a killer-cell immunoglobulin-like receptor (KIR), LAG-3 (CD223), TIM-3 (HAVCR2), CEACAM, CEACAM-1, CEACAM-3, CEACAM-5, GAL9, VISTA (PD-1H), TIGIT, LAIR1, CD160, 2B4, TGFRbeta, A2AR, GITR (CD357), CD80 (B7- 1), CD86 (B7-2), CD276 (B7-H3), VTCNI (B7-H4), MHC class I, MHC class II, GALS, adenosine, TGFR, B7-H1, 0X40 (CD134), CD94 (KLRD1), CD137 (4-1BB), CD137L (4- 1BBL), CD40, IDO, CSF1R, CD40L, CD47, CD70 (CD27L), CD226, HHLA2, ICOS (CD278), ICOSL (CD275), LIGHT (TNFSF14, CD258), NKG2a, NKG2d, OX40L (CD134L), PVR (NECL5, CD155), SIRPa, MICA / B, and / or arginase. In some embodiments, an immune checkpoint inhibitor (i.e., a checkpoint inhibitor) decreases the activity of a checkpoint protein that negatively regulates immune cell function, e.g., in order to enhance T cell activation and / or an anti-cancer immune response. In other embodiments, a checkpoint inhibitor increases the activity of a checkpoint protein that positively regulates immune cell function, e.g., in order to enhance T cell activation and / or an anti-cancer immune response. In some embodiments, the checkpoint inhibitor is an antibody. Examples of checkpoint inhibitors include, without limitation, a PD-1 axis binding antagonist, a PD-L1 axis binding antagonist (e.g., an anti-PD-Ll antibody, e.g., atezolizumab (MPDL3280A)), an antagonist directed against a co-inhibitory molecule (e.g., a CTLA-4 antagonist (e.g., an anti-CTLA-4 antibody), a TIM-3 antagonist (e.g., an anti -TIM-3 antibody), or a LAG-3 antagonist (e.g., an anti -LAG-3 antibody)), or any combination thereof. In some embodiments, the immune checkpoint inhibitors comprise drugs such as small molecules, recombinant forms of ligand or receptors, or antibodies, such as human antibodies (see, e.g., WO 2015016718; Pardoll, Nat Rev Cancer, 12(4): 252-64, 2012). In some embodiments, known inhibitors of immune checkpoint proteins or analogs thereof may be used, in particular chimerized, humanized or human forms of antibodies may be used.

[0171] For example, a PD-1 axis binding antagonist includes a PD-1 binding antagonist, a PDL1 binding antagonist and a PDL2 binding antagonist. Alternative names for “PD-1” include CD279 and SLEB2. Alternative names for “PD-L1” include B7-H1, B7-4, CD274, and B7-H. Alternative names for “PD-L2” include B7-DC, Btdc, and CD273. In some embodiments, PD- 1, PD-L1, and PD-L2 are human PD-1, PD-L1 and PD-L2.

[0172] Exemplary' immune checkpoint inhibitors include Tremelimumab (CTLA-4 blocking antibody, also known as ticilimumab, CP-675,206), anti-OX40, PD-L1 monoclonal antibody (Anti-B7-Hl; MEDI4736), MK-3475 (PD-1 blocker), nivolumab (anti-PD-1 antibody), CT-011(anti-PD-1 antibody), BY55 monoclonal antibody, AMP224 (anti-PD-Ll antibody), BMS- 936559 (anti-PD-Ll antibody), MPLDL3280A (anti-PD-Ll antibody), MSB0010718C (anti- PD-Ll antibody) and ipilimumab (anti-CTLA-4 antibody, also known as Yervoy®, MDX-010 and MDX-101). Exemplary of immunomodulatory antibodies include, but are not limited to, Daclizumab (Zenapax), Bevacizumab (Avastin ®), Basiliximab, Ipilimumab, Nivolumab, pembrohzumab, MPDL3280A, Pidilizumab (CT-011), MK-3475, BMS-936559, MPDL3280A (Atezolizumab), tremelimumab, IMP321, BMS-986016, LAG525, urelumab, PF-05082566, TRX518, MK-4166, dacetuzumab (SGN-40), lucatumumab (HCD122), SEA-CD40, CP-870, CP-893, MEDI6469, MEDI6383, MOXR0916, AMP-224, MSB0010718C (Avelumab), MEDI4736, PDR001, rHIgM12B7, Ulocuplumab, BKT140, Varlilumab (CDX-1127), ARGX- 110, MGA271, lirilumab (BMS-986015, IPH2101), IPH2201, ARGX-115, Emactuzumab, CC- 90002 and MNRP1685A or an antibody-binding fragment thereof. Other exemplary immunomodulators include, e.g., afutuzumab (available from Roche®); pegfilgrastim (Neulasta®); lenalidomide (CC-5013, Revlimid®); thalidomide (Thalomid®), actimid (CC4047); and IRX-2 (mixture of human cytokines including interleukin 1, interleukin 2, and interferon gamma, CAS 951209-71-5, available from IRX Therapeutics).

[0173] Programmed cell death 1 (PD-1) is an immune checkpoint protein that is expressed in B cells, NK cells, and T cells (Shinohara et al., 1995, Genomics 23:704-6; Blank et al., 2007, Cancer Immunol Immunother 56:739-45; Finger et al., 1997, Gene 197:177-87; Pardoll (2012) Nature Reviews Cancer 12:252-264). The major role of PD-1 is to limit the activity of T cells in peripheral tissues during inflammation in response to infection, as well as to limit autoimmunity. PD-1 expression is induced in activated T cells and binding of PD-1 to one of its endogenous ligands acts to inhibit T-cell activation by inhibiting stimulatory' kinases. PD-1 also acts to inhibit the TCR “stop signal”. PD-1 is highly expressed on Treg cells and may increase their proliferation in the presence of ligand (Pardoll (2012) Nature Reviews Cancer 12:252- 264). Anti-PD 1 antibodies have been used for treatment of melanoma, non-small-cell lung cancer, bladder cancer, prostate cancer, colorectal cancer, head and neck cancer, triple-negative breast cancer, leukemia, lymphoma and renal cell cancer (Topalian et al., 2012, N Engl J Med 366:2443-54; Lipson et al., 2013, Clin Cancer Res 19:462-8; Berger et al., 2008, Clin Cancer Res 14:3044-51; Gildener-Leapman et al., 2013, Oral Oncol 49: 1089-96; Menzies & Long, 2013, Ther Adv Med Oncol 5:278-85). Exemplary anti-PD-1 antibodies include nivolumab(Opdivo by BMS), pembrolizumab (Keytruda by Merck), pidilizumab (CT-011 by Cure Tech), lambrolizumab (MK-3475 by Merck), and AMP-224 (Merck), nivolumab (also referred to as Opdivo, BMS-936558 or MDX1106; Bristol-Myers Squibb) is a fully human IgG4 monoclonal antibody which specifically blocks PD-1. Nivolumab (clone 5C4) and other human monoclonal antibodies that specifically bind to PD-1 are described in US 8,008,449 and W02006 / 121168. Pidilizumab (CT-011; Cure Tech) is a humanized IgGlk monoclonal antibody that binds to PD- 1. Pidilizumab and other humanized anti-PD-1 monoclonal antibodies are described in W02009 / 101611. Pembrolizumab (formerly known as lambrolizumab, and also referred to as Keytruda, MK03475; Merck) is a humanized IgG4 monoclonal antibody that binds to PD-1. Pembrolizumab and other humanized anti-PD-1 antibodies are described in US 8,354,509 and W02009 / 114335. Other anti-PD-1 antibodies include AMP 514 (Amplimmune), among others, e.g., anti-PD-1 antibodies described in US 8,609,089, US 2010028330, US 20120114649 and / or US 20150210769. AMP-224 (B7-DCIg; Amplimmune; e.g., described in W02010 / 027827 and WO2011 / 066342), is a PD-L2 Fc fusion soluble receptor that blocks the interaction between PD-1 and B7-Hl.

[0174] PD-L1 (also known as CD274 and B7-H1) and PD-U2 (also known as CD273 and B7-DC) are ligands for PD-1, found on activated T cells, B cells, myeloid cells, macrophages, and some types of tumor cells. Anti-tumor therapies have focused on anti-PD-Ul antibodies. The complex of PD-1 and PD-L1 inhibits proliferation of CD8+ T cells and reduces the immune response (Topalian et al., 2012, N Engl J Med 366:2443-54; Brahmer et al., 2012, N Eng J Med 366:2455-65). Anti-PD-Ll antibodies have been used for treatment of non-small cell lung cancer, melanoma, colorectal cancer, renal-cell cancer, pancreatic cancer, gastric cancer, ovarian cancer, breast cancer, and hematologic malignancies (Brahmer et al., 2012, N Eng J Med 366:2455-65; Ott et al., 2013, Clin Cancer Res 19:5300-9; Radvanyi et al., 2013, Clin Cancer Res 19:5541; Menzies & Long, 2013, Ther Adv Med Oncol 5:278-85; Berger et al., 2008, Clin Cancer Res 14: 13044-51). Exemplary anti-PD-Ll antibodies include MDX-1105 (Medarex), MEDI4736 (Medimmune) MPDL3280A (Genentech), BMS-935559 (Bristol-Myers Squibb) and MSB0010718C. MEDI4736 (Medimmune) is ahuman monoclonal antibody that binds to PD-L1, and inhibits interaction of the ligand with PD-1. MDPL3280A (Genentech / Roche) is ahuman Fc optimized IgGl monoclonal antibody that binds to PD-L1. MDPL3280A and other human monoclonal antibodies to PD-L1 are described in U.S. PatentNo. 7,943,743 and U.S Publication No. 20120039906. Other anti-PD-Ll binding agents include YW243.55.S70 (see W02010 / 077634) and MDX-1105 (also referred to as BMS-936559, and, e.g., anti-PD-Ll binding agents described in W02007 / 005874).

[0175] Also provided herein are methods for treating or delaying the development or progression of cancer in an individual, comprising administering to the subject an effective amount of an additional therapeutic agent, such as an immune checkpoint inhibitor, and a fusion protein, nucleic acid construct or composition.

[0176] The additional therapeutic agent and the fusion protein or nucleic acid construct may be administered in any order. For example, an additional therapeutic agent and a fusion protein or nucleic acid construct may be administered sequentially (at different times) or concurrently (at the same time). In some embodiments, an additional therapeutic agent and a fusion protein or nucleic acid construct are in separate compositions. In some embodiments, an additional therapeutic agent and a fusion protein or nucleic acid construct are in the same composition.

[0177] In some embodiments, prior to treatment with an additional therapeutic agent and fusion proteins or nucleic acid constructs in accordance with any of the methods described herein, the individual has progressed after treatment with or failed to respond adequately to treatment with a monotherapy of the additional therapeutic agent, e.g., treatment with an immune checkpoint inhibitor, e.g., anti-PD-1 antibody.

[0178] The additional therapeutic agent and the fusion protein or nucleic acid construct may be administered by the same route of administration or by different routes of administration. In some embodiments, the additional therapeutic agent is administered intravenously, intramuscularly, subcutaneously, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally.

[0179] In some embodiments, the methods may further comprise an additional therapy. The additional therapy may be radiation therapy, surgery (e.g., lumpectomy and a mastectomy), chemotherapy, gene therapy, DNA therapy, viral therapy, RNA therapy, immunotherapy, bone marrow transplantation, nanotherapy, monoclonal antibody therapy, or a combination of the foregoing. The additional therapy may be in the form of adjuvant or neoadjuvant therapy. In some embodiments, the additional therapy is the administration of small molecule enzymatic inhibitor or anti-metastatic agent. In some embodiments, the additional therapy is the administration of side-effect limiting agents (e.g., agents intended to lessen the occurrenceand / or severity of side effects of treatment, such as anti-nausea agents, etc.). In some embodiments, the additional therapy is radiation therapy. In some embodiments, the additional therapy is surgery. In some embodiments, the additional therapy is a combination of radiation therapy and surgery. In some embodiments, the additional therapy is gamma irradiation.

[0180] In some aspects, the fusion proteins, nucleic acid constructs or compositions comprising the same, are administered together with an adjuvant. Exemplary adjuvants include, but are not limited to, alum (aluminum salts), oil-in-water emulsions, water-in-oil emulsions, liposomes, and microparticles, such as poly(lactide-co-glycolide) microparticles (Shah et al., Methods Mol Biol, 1494: 1-14, 2017). In some embodiments, the compositions further comprises an aluminum salt adjuvant to which the nucleic acid construct encoding the vaccine epitope and C-degron peptide is adsorbed. In some embodiments, the aluminum salt adjuvant comprises one or more of the group consisting of amorphous aluminum hydroxyphosphate sulfate, aluminum hydroxide, aluminum phosphate, and potassium aluminum sulfate. In some embodiments, the aluminum salt adjuvant comprises one or both of aluminum hydroxide and aluminum phosphate. In some embodiments, the aluminum salt adjuvant consists of aluminum hydroxide. Other exemplary adjuvants include, but are not limited to, squalene-in-water emulsion (e.g., MF59 or AS03), and / or a saponin such as Quil A or QS-21, as in AS01 or AS02), and resiquimod.IV. DEFINITIONS

[0181] Unless defined otherwise, all terms of art, notations and other technical and scientific terms or terminology used herein are intended to have the same meaning as is commonly understood by one of ordinary' skill in the art to which the claimed subject matter pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and / or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art.

[0182] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. For example, "a" or "an" means "at least one" or "one or more.

[0183] The term "about" as used herein refers to the usual error range for the respective value readily known to the skilled person in this technical field. Reference to "about" a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se.

[0184] Throughout this disclosure, various aspects of the claimed subject matter are presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the claimed subject matter. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, where a range of values is provided, it is understood that each intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the claimed subject matter. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the claimed subject matter, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the claimed subject matter. This applies regardless of the breadth of the range.

[0185] The terms “nucleic acid” and “nucleotide” include naturally-occurring species or functional analogs thereof, or variants thereof. A nucleic acid can contain nucleotides having any of a variety of analogs of these sugar moieties that are established in the field. A nucleic acid can include native or non-native nucleosides. In this regard, a native ribonucleic acid (RNA) can have one or more nucleosides selected from the group consisting of uridine (U), adenosine (A), cytidine (C), or guanosine (G). Useful non-native nucleosides are established in the field, such as a pseudouridine in place of a uridine.

[0186] In some embodiments, “treatment” (and grammatical variations thereof such as “treat” or “treating”) refers to complete or partial amelioration or reduction of a disease or condition or disorder, or a symptom, adverse effect or outcome, or phenotype associated therewith. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, dimimshment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improvedprognosis. The terms do not imply complete curing of a disease or complete elimination of any symptom or effect(s) on all symptoms or outcomes.

[0187] In some embodiments, “preventing,” as used herein, includes providing prophylaxis with respect to the occurrence or recurrence of a disease in a subject that may be predisposed to the disease but has not yet been diagnosed with the disease. In some embodiments, the provided molecules and compositions are used to delay development of a disease or to slow the progression of a disease. A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically but not necessarily, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount. In some embodiments, the subject is a human.

[0188] A “therapeutically effective amount” of an agent, e.g., a pharmaceutical formulation, binding molecule, or cells, refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result, such as for treatment of a disease, condition, or disorder, and / or pharmacokinetic or pharmacodynamic effect of the treatment. The therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the subject, and the populations of cells administered. In some embodiments, the provided methods involve administering the fusion protein, nucleic acid constructs, and / or compositions at effective amounts, e.g., therapeutically effective amounts.

[0189] A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically but not necessarily, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.

[0190] As used herein, a “subject” is a mammal, such as a human or other animal, and typically is human.

[0191] As used herein, “delaying development of a disease" means to defer, hinder, slow, retard, stabilize, suppress and / or postpone development of the disease (such as cancer). This delay can be of varying lengths of time, depending on the history of the disease and / or individual being treated. As is evident to one skilled in the art, a sufficient or significant delaycan, in effect, encompass prevention, in that the individual does not develop the disease. For example, a late stage cancer, such as development of metastasis, may be delayed.

[0192] The term “peptide” as used herein refers to a molecule comprising an amino acid sequence of between 2 and 200 amino acids, connected by peptide bonds, but which can comprise non-amino acid structures. Peptides according to the invention can contain any of the conventional 20 amino acids or modified versions thereof, or can contain non-naturally occurring amino-acids incorporated by chemical peptide synthesis or by chemical or enzymatic modification.

[0193] The term “antigen” as used herein refers to a structure of a macromolecule, typically protein (with or without polysaccharides) or made of proteinaceous composition and comprising T cell or B cell epitopes.

[0194] The term “epitope” refers to one or several portions (which may define a conformational epitope) of an antigenic protein which is / are specifically recognized and bound by an antibody or a portion thereof or a receptor presented at the cell surface of a B or T cell lymphocyte, and which is able, by said binding, to induce an immune response. The term “T cell epitope” in the context of the present invention refers to a dominant, sub-dominant or minor T cell epitope, i.e., a part of an antigenic protein that is specifically recognized and bound by a receptor at the cell surface of a T lymphocyte. Whether an epitope is dominant, sub-dominant or minor depends on the immune reaction elicited against the epitope. Dominance depends on the frequency at which such epitopes are recognized by T cells and able to activate them, among all the possible T cell epitopes of a protein.

[0195] In some aspects, a T cell epitope is an epitope recognized by MHC class II molecules, which typically includes about 8-10 amino acids which fit in the groove of the MHC II molecule. Peptides recognized by MHC class II molecules and not by MHC class I molecules are referred to as MHC class II restricted T cell epitopes.

[0196] The term “MHC” refers to “major histocompatibility antigen”. In humans, the MHC genes are known as HLA (“human leukocyte antigen”) genes. Although there is no consistently followed convention, some literature uses HLA to refer to HLA protein molecules, and MHC to refer to the genes encoding the HLA proteins. As such the terms “MHC” and “HLA” are equivalents when used herein.

[0197] The term “sequence identity” of two sequences as used herein relates to the number of positions with identical nucleotides or amino acids divided by the number of nucleotides or amino acids in the shorter of the sequences, when the two sequences are aligned. In particular, the sequence identity is from 70% to 80%, from 81% to 85%, from 86% to 90%, from 91% to 95%, from 96% to 100%, or 100%.

[0198] The terms “peptide-encoding nucleic acid” and “nucleic acid encoding peptide” as used herein refer to a nucleotide sequence, which, when expressed in an appropriate environment, results in the generation of the relevant peptide sequence or a derivative or homologue thereof. Such polynucleotides or nucleic acids include the normal sequences encoding the peptide, as well as derivatives and fragments of these nucleic acids capable of expressing a peptide with the required activity. The nucleic acid encoding a peptide according to the invention or fragment thereof is a sequence encoding the peptide or fragment thereof originating from a mammal or corresponding to a mammalian, most particularly a human peptide fragment.

[0199] The term “immune disorders” or “immune diseases” refers to diseases wherein a reaction of the immune system is responsible for or sustains a malfunction or non-physiological situation in an organism. Included in immune disorders are, inter alia, allergic disorders and autoimmune diseases.

[0200] The terms “allergic diseases” or “allergic disorders” as used herein refer to diseases characterized by hypersensitivity reactions of the immune system to specific substances called allergens (such as pollen, stings, drugs, or food). Allergy is the ensemble of signs and symptoms observed whenever an atopic individual patient encounters an allergen to which he has been sensitized, which may result in the development of various diseases, in particular respiratory diseases and symptoms such as bronchial asthma. Various types of classifications exist and mostly allergic disorders have different names depending upon where in the mammalian body it occurs. “Hypersensitivity” is an undesirable (damaging, discomfortproducing and sometimes fatal) reaction produced in an individual upon exposure to an antigen to which it has become sensitized; “immediate hypersensitivity” depends of the production of IgE antibodies and is therefore equivalent to allergy.

[0201] The term “natural” when referring to a peptide relates to the fact that the sequence is identical to a fragment of a naturally occurring protein (wild type or mutant). In contrast, theterm “artificial” refers to a sequence which as such does not occur in nature. An artificial sequence is obtained from a natural sequence by limited modifications such as changing / deleting / inserting one or more amino acids within the naturally occurring sequence or by adding / removing amino acids N- or C-terminally of a naturally occurring sequence.V. EXEMPLARY EMBODIMENTS

[0202] Among the provided embodiments are:1. A fusion protein comprising a vaccine epitope and a C-degron peptide.2. The fusion protein of embodiment 1, wherein the C-degron peptide is at least 2 amino acids in length.3. The fusion protein of embodiment 1 or 2, wherein the C-degron peptide is at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids in length.4. The fusion protein of any of embodiments 1-3, wherein the C-degron peptide is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids in length.5. The fusion protein of any of embodiments 1-4, wherein the C-degron peptide comprises an E3 ubiquitin ligase target motif.6. The fusion protein of embodiment 5, wherein the E3 ubiquitin ligase target motif compnses a target motif of DoalO, MARCHF6, CRL2, NOT4, ELOB, ELOC, DDB1, CUL2, CUL4, KLHDC1, KLHDC2, KLHDC3, KLHDC10, FEM1A, FEM1B, FEM1C, APPBP2, DCAF12, TRPC4AP, UBC6, UBC7, UBR1, UBR2, UBR4, and / or UBR5.7. The fusion protein of embodiment 5 or 6, wherein the E3 ubiquitin ligase target motif comprises atarget motif of DoalO or MARCHF6.8. The fusion protein of any of embodiments 1-7, wherein the C-degron peptide comprises an FSSL-like sequence.9. The fusion protein of any of embodiments 1-8, wherein the C-degron peptide comprises the following formula: [F,W or Y]-[S or T]-[S or T]-[I, L or V]-XX- [hydrophobic]-X-[I, L or V]-[H-bond acceptor], wherein X is any amino acid.10. The fusion protein of any of embodiments 1-6, wherein the C-degron peptide comprises a CL1, a CL2, a CL6, a CL9, a CLIO, a CL11, a CL12, a CL15, or a CL16 sequence or a variant thereof.11. The fusion protein of any of embodiments 1-6 and 10, wherein the C-degron peptide comprises the sequence set forth in any one of SEQ ID NOS: 1 and 39-46, a contiguous portion of any one of SEQ ID NOS: 1 and 39-46 of at least 4 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing.12. The fusion protein of any of embodiments 1-11, wherein the C-degron peptide comprises a CL1 sequence or a variant thereof.13. The fusion protein of any of embodiments 1-12, wherein the C-degron peptide comprises the sequence set forth in SEQ ID NO: 1, a contiguous portion of SEQ ID NO: 1 of at least 4 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing.14. The fusion protein of any of embodiments 1-13, further comprising one or more additional vaccine epitopes.15. The fusion protein of any of embodiments 1-14, wherein the C-degron peptide is located C-terminal to the vaccine epitopes.16. The fusion protein of any of embodiments 1-15, wherein the vaccine epitope comprises an infectious disease vaccine epitope, optionally a viral vaccine epitope.17. The fusion protein of any of embodiments 1-16, wherein the vaccine epitope comprises a cancer epitope.18. The fusion protein of embodiment 17, wherein the cancer epitope is a cancer neoantigen epitope.19. The fusion protein of embodiment 17 or 18, wherein the cancer neoantigen epitope comprises a cancer epitope selected from among MEI, M26, Gludl, Mtchl, Ml 8, and E2f8.20. The fusion protein of any of embodiments 17-19, wherein the vaccine epitope independently comprises a sequence selected from the sequence set forth in SEQ ID NOS:2-8, a contiguous portion of a sequence selected from the sequence set forth in SEQ ID NOS:2-8 of at least 8 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing.21. The fusion protein of any of embodiments 1-20, further comprising one or more peptide linkers.22. The fusion protein of embodiment 21, wherein the one or more peptide linkers are located between the vaccine epitope and the C-degron peptide.23. The fusion protein of embodiment 21 or 22, wherein the one or more peptide linkers are located between different vaccine epitopes.24. The fusion protein of any of embodiments 21-23, wherein the one or more peptide linkers independently comprises a natural linker comprising 5 or more adjacent amino acids that naturally occur in the N- terminal or C-terminal of the vaccine epitope.25. The fusion protein of any of embodiments 21-24, wherein the one or more peptide linkers independently comprises a natural linker comprising 8, 9, 10, 11, 12, 13, 14, 15, or 16 or more adjacent amino acids that naturally occur in the N- terminal or C-terminal of the vaccine epitope.26. The fusion protein of any of embodiments 21-25, wherein the one or more peptide linkers independently comprises the sequence set forth in any one of SEQ ID NOS:28-38, a contiguous portion of any one of SEQ ID NOS:28-38 of at least 8 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing.27. The fusion protein of any of embodiments 1-26, wherein when the fusion protein is expressed in a subject, an immune response to the vaccine epitope is increased compared to a subject without expression of the fusion protein.28. The fusion protein of embodiment 27, wherein the immune response comprises CD4+ T cell response, CD8+ T cell response and / or antibody response.29. The fusion protein of embodiment 27 or 28, wherein the immune response comprises CD4+ T cell response or CD8+ T cell response.30. A nucleic acid construct encoding the fusion protein of any of embodiments 1-29.31. The nucleic acid construct of embodiment 30, further comprising a translation initiation element.32. The nucleic acid construct of embodiment 31, wherein the translation initiation element is an internal ribosome entry site (IRES) or a Translation Initiator of Short 5' UTR (TISU) element.33. The nucleic acid construct of embodiment 31 or 32, wherein the translation initiation element comprises the sequence set forth in SEQ ID NO:27, or a sequence that has at least at orabout 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to the sequence set forth in SEQ ID NO:27.34. The nucleic acid construct of any of embodiments 30-33, wherein the nucleic acid comprises an RNA.35. The nucleic acid construct of any of embodiments 30-33, wherein the nucleic acid comprises a circular RNA.36. The nucleic acid construct of any of embodiments 30-33, wherein the nucleic acid comprises a linear RNA.37. The nucleic acid construct of any of embodiments 30-33, wherein the nucleic acid comprises a cleaved linear RNA comprising a hydroxyl group at the 5' terminus, and a 2', 3'- cyclic phosphate at the 3' terminus.38. The nucleic acid construct of any of embodiments 30-33, wherein the nucleic acid comprises a messenger RNA.39. The nucleic acid construct of any of embodiments 30-33, wherein the nucleic acid comprises DNA.40. A composition comprising the fusion protein of any of embodiments 1-29 or the nucleic acid construct of any of embodiments 30-39.41. The composition of embodiment 40, wherein the composition is a pharmaceutical composition.42. The composition of embodiment 40 or 41, wherein the composition comprises a pharmaceutically acceptable excipient.43. The composition of any of embodiments 40-42, wherein the composition comprises a lipid nanoparticle (LNP).44. The composition of any of embodiments 40-42, wherein the composition comprises a lipoplex (LPX).45. A method of vaccinating a subject, the method comprising administering the fusion protein of any of embodiments 1-29, the nucleic acid construct of any of embodiments 30-39, or the composition of any of embodiments 40-44, to the subject.46. A method for enhancing vaccine epitope presentation to elicit an immune response in the subject, the method comprising administering the fusion protein of any of embodiments1-29, the nucleic acid construct of any of embodiments 30-39, or the composition of any of embodiments 40-44, to the subject.47. The method of embodiment 45 or 46, wherein the subject has a disease or disorder.48. A method of treating a disease or disorder in the subject, the method comprising administering the fusion protein of any of embodiments 1-29, the nucleic acid construct of any of embodiments 30-39, or the composition of any of embodiments 40-44, to the subject.49. The method of any of embodiments 45-48, wherein an immune response to the vaccine epitope is increased compared to a subject without expression of the fusion protein.50. The method of embodiment 49, wherein the immune response comprises CD4+ T cell response, CD8+ T cell response and / or antibody response.51. The method of embodiment 49 or 50, wherein the immune response comprises CD4+ T cell response or CD8+ T cell response.52. The method of any of embodiments 45-51, wherein the method prevents or reduces the severity of a disease or disorder associated with the vaccine epitope in the subject.53. The method of any of embodiments 47-52, wherein the disease or disorder is an infectious disease, optionally a viral infection.54. The method of any of embodiments 47-53, wherein the disease or disorder is cancer.55. The fusion protein of any of embodiments 1-29, the nucleic acid construct of any of embodiments 30-39, or the composition of any of embodiments 40-44 for use in vaccinating a subject, wherein the fusion protein, the nucleic acid construct or the composition is administered to the subject.56. The fusion protein of any of embodiments 1-29, the nucleic acid construct of any of embodiments 30-39, or the composition of any of embodiments 40-44 for use in enhancing an immune response to a vaccine epitope in a subject, wherein the fusion protein, the nucleic acid construct or the composition is administered to the subject.57. The fusion protein of any of embodiments 1-29, the nucleic acid construct of any of embodiments 30-39, or the composition of any of embodiments 40-44 for use in treating a disease or disorder in a subject, wherein the fusion protein, the nucleic acid construct or the composition is administered to the subject.58. Use of the fusion protein of any of embodiments 1-29, the nucleic acid construct of any of embodiments 30-39, or the composition of any of embodiments 40-44 in themanufacture of medicament for vaccinating a subject, wherein the medicament is administered to the subject.59. Use of the fusion protein of any of embodiments 1-29, the nucleic acid construct of any of embodiments 30-39, or the composition of any of embodiments 40-44 in the manufacture of medicament for enhancing an immune response to a vaccine epitope in a subject, wherein the medicament is administered to the subject.60. Use of the fusion protein of any of embodiments 1-29, the nucleic acid construct of any of embodiments 30-39, or the composition of any of embodiments 40-44 in the manufacture of medicament for treating a disease or disorder in a subject, wherein the medicament is administered to the subject.VI. EXAMPLES

[0203] The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.Example 1 Generation of constructs encoding epitope-C-degron peptide fusion proteins

[0204] Various nucleic acid constructs encoding a fusion protein of various exemplary vaccine epitopes and with an exemplary C-degron peptide were designed and tested for efficiency in the presentation of the various epitopes.

[0205] As an exemplary method, six (6) different neoantigen epitopes (also called neoepitopes), for example, including those known to stimulate CD4+T cells (MEI) and those known to stimulate CD8+T cells (AHI, E2f8, Gludl, Mtchl, and Ml 8) were tested based on the CT26 model, a colon cancer with Balb / c background. The sequence of the tested neoepitopes are set forth in Table El below:Table El. Neoepitopes

[0206] CL 1 is an exemplary C-degron peptide that comprises a short linear motif that comprises an FSSL-like sequence, and is thought to be a substrate for the E3 ubiquitin ligase membrane-associated ring-CH finger protein 6 (MARCHF6), to mediate degradation of the fusion protein by the ubiquitin-dependent system (FIG. 1). To assess the effect of CL1 on neoantigen epitope presentation and neoantigen-dependent T cell response, RNA constructs were generated encoding a fusion protein of the various neoantigen epitopes listed above and CL1 at the C-terminal of the neoantigen epitopes (NeoAg-CLl construct in FIG. 2A; DNA sequence set forth in SEQ ID NO: 19). A construct encoding the same neoantigens without C- degron motif (naked neoantigens, NeoAg construct in FIG. 2A; DNA sequence set forth in SEQ ID NO: 17), and a construct encoding the neoantigens and an MHC class I trafficking signal (MITD) and N-terminal leader peptide of MITD fused to the C- and N-terminus of the neoantigens (NeoAg-MITD construct in FIG. 2A; DNA sequence set forth in SEQ ID NO: 18), were tested as negative and positive controls, respectively.

[0207] The RNA constructs encoding all six neoepitopes under the control of a full-length coxsackievirus B3 internal ribosome entry site (CVB3 IRES) were synthesized by in vitro transcription and circularized by engineering a group I intron method. Circular RNA was purified by HPLC.

[0208] As shown in FIG. 2B, all HPLC-purified circular RNAs (circRNA) showed over 90% circularization.Example 2 Encapsulation of constructs and in F / FO distribution assessment

[0209] The circRNA generated generally as described in Example 1 above were encapsulated with lipoplex (LPX) nanoparticles.

[0210] Briefly, liposomes were prepared using the NanoAssemblr Platform (Precision Nanosystems Inc., Vancouver, BC, Canada). Lipid mixtures composed of DOTMA and DOPE were prepared at a 2: 1 ratio. Phosphate-buffered saline (PBS) was used as the aqueous phase. For all formulations, the organic and an aqueous phase were injected simultaneously in the micromixer, the particles were collected and dialyzed at room temperature overnight against 10 mM Tris-HCl buffer (pH 7.4) for removal of residual organic solvent. After determining the DOTMA concentration, the LPX preparation was assembled with a 1.3:2 charge ratio of liposome (DOTMA) to RNA. For calculating the molar ratio between RNA and DOTMA, amean molar mass of 330 Da per nucleotide and one negative charge per phosphodi ester was assumed. For DOTMA one positive charge per molecule was assumed. The prepared encapsulated circRNA was administered to mice for vaccination.

[0211] Distribution of LPX-mediated in vivo organ delivery was first tested by encapsulating an mRNA encoding firefly luciferase with LPX as described above and intravenously injected it into Balb / c mice (10 pig / 100 pl per injection). 24 hours after injection, mice were sacrificed and distribution of luciferase activity was assessed. As seen in FIG. 3, LPX was selectively delivered into the spleens as compared to luciferase activity in liver and lung. Luciferase activity in the spleen was 128 and 36 times higher than those of liver and lung respectively.Example 3 Effect of a C-degron peptide in the presentation of neoepitopes and induction of neoepitope-specific immune responses

[0212] The efficiency of various nucleic acid molecules encoding fusion proteins of multiple epitopes and a C-degron peptide, or an MHC trafficking signal, were assessed for the ability to induce neoepitope-specific immune responses.

[0213] Circular RNA constructs encoding naked neoepitopes (NeoAg), neoepitopes fused to MITD (NeoAg-MITD), and neoepitopes fused to CL1 (NeoAg-CLl), described in Example 1 and FIG. 2A above, were encapsulated with LPX nanoparticles generally as described in Example 2 and intravenously injected into Balb / c mice on day 0, 2, and 7.

[0214] On day 10, spleens were isolated from the mice and were measured for their weight and neoepitope-specific immune responses. The weight of the spleens isolated from mice administered NeoAg was significantly heavier than that of NaCl-injected control mice. Although there was no significant difference in spleen weight between mice administered NeoAg-MITD and NeoAg-CLl, the spleen weight of mice administered NeoAg-CLl were more substantially increased than those administered NeoAg-MITD compared to the control group treated with NaCl (p=0.0009 vs 0.0189) (FIG. 4A).

[0215] Splenocytes were isolated and stimulated with the same neoepitope peptides encoded by the circRNA constructs (MEI, AHI, E2f8, Gludl, or Mtchl). ELISPOT assay for IFN-y was performed on splenocytes from the vaccinated and control mice. Briefly, the wells pre-coated with anti-mouse IFN-y antibody were washed with PBS and blocked with RPML1640 medium with 10% FBS for 30 min. Splenocytes were plated at 2 x 105cells / well, in duplicate, with the CT26 neoepitopes outlined in Example 1 at the final concentration of 2 pg / ml. After overnight stimulation at 37 °C, plates were washed and incubated with biotinylated anti-mouse IFN-y antibody, and incubated for 1 h at room temperature with streptavidin- AP conjugated antibody. After washing, 100 pl / well of the substrate (NBT / BCIP-1 solution) was added to measure spot development. After incubation of about 30 min at RT, the plates were thoroughly washed with distilled water to stop the reaction. Plates were allowed to air-dry completely, and spots were counted using an automated ELISPOT reader (Mabtech, ASTORTM ELISpot Reader).

[0216] When a peptide for stimulating CD4+T cells (MEI) was added, splenocytes from mice administered NeoAg-CLl showed substantially higher increase in IFN-y production compared to splenocytes from mice administered NeoAg-MITD, each increase assessed over the splenocytes from control mice treated with NaCl (p-value=0.0034 vs 0.0079, respectively, see FIG. 4B). Similarly, in the case of CD8+T cell response (AHI), administration of NeoAg- CL1 showed substantially higher increase in IFN-y production over control mice treated with NaCl, compared to the increase observed from the administration NeoAg-MITD (p- value=0.0031 vs 0.0107, respectively, FIG. 4C).

[0217] In addition, for Mtchl (CD8+T cell neoepitope), administration of NeoAg-CLl showed substantially higher IFN-y production over control mice treated with NaCl, compared to the increase observed from the administration NeoAg-MITD (p-value, 0.0007 vs 0.0162, respectively, FIG. 4D). Additionally, administration of NeoAg-CLl produced significantly higher IFN-y than administration of the naked neoepitope construct (NeoAg) (p=0.0056), while NeoAg-MITD did not (FIG. 4D). In response to E2f8 (CD8+T cell neoepitope), administration of NeoAg-CLl showed substantially higher IFN-y production over control mice treated with NaCl, compared to the increase observed from the administration NeoAg-MITD (p- value=0.0033 vs 0.0068, FIG. 4E). In response to Gludl (CD8+T cell neoepitope), administration of NeoAg-MITD showed substantially higher IFN-y production over control mice treated with NaCl, compared to the increase observed from the administration NeoAg- CLl (p-value <0.0001 vs 0.0054, respectively, FIG. 4F). Naked neoepitope (NeoAg) did not induce a substantial T cell response compared to control (NaCl-treated group) for all fiveneoepi topes, supporting that the degron motifs CL1 and MITD play a critical role in vaccine epitope presentation and effectively inducing T cell responses to neoepitopes. Taken together, the constructs NeoAg-CLl and NeoAg-MITD substantially increased IFN-y production compared to NeoAg or NaCl control, supporting the utility of an exemplary C-degron peptide CL1 motif and MITD in vaccine antigen presentation and effectively inducing T cells responses against epitopes contained in the fusion protein. Furthermore, NeoAg-CLl was observed to be overwhelmingly more effective (four out of five neoepitopes) in inducing neoepitopes-specific T cells responses compared to NeoAg-MITD. The results support the advantage and utility of an exemplary C-degron peptide CL1 in a fusion protein for efficient in vivo neoepitope presentation and enhancing immune responses against the epitopes.Example 4 Assessment of linkers on immune response to neoepitopes fused with a C- degron peptide

[0218] The effect of different linkers connecting the neoepitopes in the fusion protein encoding constructs was assessed for effective cleavage and subsequent induction of a T cell immune response via antigen presentation.

[0219] Different linkers connecting the six (6) neoepitopes in a circular RNA construct were tested. The first tested linker was a 10-mer non-immunogenic glycine / serine linker (GS linker; set forth in SEQ ID NO: 14) and the others were natural sequences at the N- and C- terminus of each neoepitope (natural linkers, set forth in SEQ ID NOS: 28-38) (see FIG. 5A). In the GS linker construct, 6 neoepitopes and CL1 were connected with the GS linker (NeoAg- CLl (GS linker) or NeoAg-CLl-GS; DNA sequence set forth in SEQ ID NO: 19). In the natural linker construct, the Ml 8 neoepitope was replaced with Steap (epitope sequence set forth in SEQ ID NO: 7), the FLAG sequence was removed, and the 6 neoepitopes and CL1 were connected with the natural sequence linker (NeoAg-CLl (natural linker) or NeoAg-CLl -N; DNA sequence set forth in SEQ ID NO:20). CircRNA was generated from the NeoAg-CLl (GS linker) and the NeoAg-CLl (natural linker) constructs. The sequences were synthesized and purified by HPLC (which showed that circRNA purity is at least 90% for both constructs), and encapsulated with LPX as described in Example 2 (FIG. 5B).

[0220] The encapsulated circRNA constructs were intravenously injected into Balb / c mice on day 0, 2, and 7. On day 10, splenocytes were isolated from the mice administered eachconstruct and restimulated with AHI (for CD8+ T cells) or MEI (for CD4+ T cells) neoepitope peptides. INF-y production was assessed by ELISPOT assay as described in Example 3.

[0221] As shown in FIG. 5C, administration of NeoAg-CLl-N induced more substantial INF-y production in response to MEI neoepitope peptide stimulation over NaCl injected negative control, as compared to administration ofNeoAg-CLl-GS (p-value 0.0002 vs 0.0026). Similarly, administration of NeoAg-CLl-N induced more substantial INF-y production in response to AHI neoepitope peptide stimulation over NaCl injected negative control, as compared to administration ofNeoAg-CLl-GS (p-value 0.048 vs 0.075, FIG. 5D).

[0222] The results support that administration of neoepitope-encoding constructs where the various epitopes in the fusion protein are connected with natural linkers can induce a stronger T cell response compared to similar constructs in which the various epitopes in the fusion protein are connected with a glycine / serine linker. Further, the results support the advantage and utility of natural linkers for connecting various epitopes in a multi-epitope construct that comprises an exemplary C-degron peptide, for efficient in vivo antigen presentation and the induction of T cell immune response against the vaccine epitopes.Example 5 Assessing antigen presentation and immune response of circRNA encoding epitope-CLl and linear mRNA encoding epitope-MITD

[0223] The immune response to antigen presentation via mRNA encoding neoepitopes fused with MITD motif were compared with that of antigen presentation via circular RNA encoding neoepitopes fused with an exemplary C-degron peptide CL1.

[0224] mRNA was generated containing the following: 5’ cleanCap, MITD signal peptide (SP), the 6 neoepitopes (MEI, AHI, E2f8, Gludl, Mtchl, Steap) linked together with natural sequences followed by a MITD motif, and a 3’poly adenylation (NeoAg-MITD mRNA in FIG. 6A or MITD mRNA; DNA sequence set forth in SEQ ID NO:21). CircRNA fromNeoAg-CLl with natural linkers (NeoAg-CLl circRNA in FIG 6A or CL1 circRNA; DNA sequence set forth in SEQ ID NO:20) was generated as described in Examples 1 and 4. CircRNA comprising NeoAg-CLl or mRNA comprising NeoAg-MITD was encapsulated with LPX nanoparticles, generally as described in Example 2 above, and intravenously injected into Balb / c mice on day 0, 5, and 7.

[0225] On day 14, the spleens were isolated from the mice and the spleen weights were measured. Splenocytes were isolated and stimulated with AHI, E2f8 (for CD8+T cells), or MEI (for CD4+T cells) neoepitope peptides to measure INF-y production, as described in Example 3.

[0226] Although there were no significant differences in spleen weight between mice administered with MITD mRNA and CL1 circRNA, the average spleen weight of mice administered NeoAg-CLl circRNA was higher than those of mice administered NeoAg-MITD mRNA, both comparing with control mice injected with NaCl (FIG. 6B, p =0.0002 vs 0.06). Similar results were observed in T cells’ response to neoepitope (MEI peptide for CD4+T cells, AHI and E2f8 for CD8+T cells). There were no significant differences in both CD4+T cells and CD8+T cells responses between MITD mRNA and CL1 circRNA administered mice. However, both CD4+and CD8+T cells responses of mice administered with CL1 circRNA were more substantial than those of mice administered MITD mRNA, each compared with control mice injected with NaCl (MEI, FIG. 6C (p=0.0004 vs 0.0191); AHI, FIG. 6D (p=0.0457 vs n.s.); and E2F8, FIG. 6E (p=0.0001 vs 0.0084)).

[0227] These results support the utility of circular RNA constructs comprising multiple vaccine epitopes and an exemplary C-degron peptide in an efficient in vivo antigen presentation and the induction of specific T cell immune response against the vaccine epitopes.Example 6 Assessment of anti-tumor effect of neoepitopes fused with a C-degron peptide and a PD-1 inhibitor

[0228] The anti -tumor effects and immune responses from vaccinating a subject with a construct encoding a fusion protein of cancer epitopes and an exemplary C-degron peptide, CL1, were assessed in combination with a checkpoint inhibitor anti-cancer therapy.

[0229] CT26 (a murine colorectal carcinoma cell line) cells were implanted in Balb / c mice in a syngeneic tumor model. Tumor-bearing mice were treated four times (days 5, 7, 12, and 17 after tumor implantation) with a circRNA encoding cancer neoepitopes fused to a CL 1 (NeoAg- CL1), an anti-PD-1 antibody (PD-1 Ab) as a PD-1 inhibitor, or a combination of both NeoAg- CL1 and a PD-1 inhibitor (PD-1 Ab + NeoAg-CLl) (FIG. 7A).

[0230] Treatment with NeoAg-CLl alone did not suppress the tumor growth or substantially improve survival rate compared with those of the isotype control group (FIGS.7B-7C). However, the combination therapy using NeoAg-CLl and PD-1 inhibitor significantly suppressed the tumor growth (FIG. 7B) and improved the survival rate (FIG. 7C) compared with those of NeoAg-CLl monotherapy group or the control group. Additionally, the combination therapy was more effective in suppressing tumors and improving the survival rate than the PD-1 inhibitor monotherapy group.

[0231] 40 days after the tumor implantation, splenocytes were isolated from each treated group to analy ze T cell response after stimulation with the neoepitopes encoded by the NeoAg- CLl construct.

[0232] For both CD4+and CD8+T cells responses, the PD-1 Ab + NeoAg-CLl combination therapy group induced significantly higher IFN-y production compared with those of NeoAg-CLl monotherapy (p<0.0001 for MEI stimulation, FIG. 7D; p=0.0011 for AHI stimulation, FIG. 7E) or PD-1 monotherapy (p=0.0002 for MEI stimulation, FIG. 7D; p=0.0003 for AHI stimulation, FIG. 7E) monotherapy. Furthermore, the PD-1 inhibitor monotherapy group produced more IFN-y from CD4+T cells (MEI peptide) compared to the NeoAg-CLl monotherapy group (p=0.0028; FIG. 7D), which is not observed from CD8+T cell (AHI peptide) response (FIG. 7E).

[0233] Taken together, these results support that antigen presentation using vaccine epitopes and an exemplary C-degron peptide CL1, when used in combination with a checkpoint inhibitor therapy such as a PD-1 inhibitor, enhanced the anti -tumor effect, as shown by suppression of tumor growth and improvements in the survival rate, in some aspects by enhancing cancer neoepitopes-specific T cell responses. These results support the utility of constructs comprising vaccine epitopes and an exemplary C-degron peptide in enhancing antitumor immune responses, suppression of tumor growth and promoting survival of a subject with a tumor.

[0234] The present invention is not intended to be limited in scope to the particular disclosed embodiments, which are provided, for example, to illustrate various aspects of the invention. Various modifications to the compositions and methods described will become apparent from the description and teachings herein. Such variations may be practiced withoutdeparting from the true scope and spirit of the disclosure and are intended to fall within the scope of the present disclosure.SEQUENCES

Claims

CLAIMS1. A fusion protein comprising a vaccine epitope and a C-degron peptide.

2. The fusion protein of claim 1, wherein the C-degron peptide is at least 2 amino acids in length.

3. The fusion protein of claim 1 or 2, wherein the C-degron peptide is at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 ammo acids in length.

4. The fusion protein of any of claims 1-3, wherein the C-degron peptide is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 ammo acids in length.

5. The fusion protein of any of claims 1-4, wherein the C-degron peptide comprises an E3 ubiquitin ligase target motif.

6. The fusion protein of claim 5, wherein the E3 ubiquitin ligase target motif comprises a target motif of DoalO, MARCHF6, CRL2, NOT4, ELOB, ELOC, DDB1, CUL2, CUL4, KLHDC1, KLHDC2, KLHDC3, KLHDC10, FEM1A, FEM1B, FEM1C, APPBP2, DCAF12, TRPC4AP, UBC6, UBC7, UBR1, UBR2, UBR4, and / or UBR5.

7. The fusion protein of claim 5 or 6, wherein the E3 ubiquitin ligase target motif comprises atarget motif of DoalO or MARCHF6.

8. The fusion protein of any of claims 1-7, wherein the C-degron peptide comprises an FSSL-like sequence.

9. The fusion protein of any of claims 1-8, wherein the C-degron peptide comprises the following formula: [F,W or Y]-[S or T]-[S or T]-[I, L or V]-XX-[hydrophobic]-X-[I, L or V]-[H-bond acceptor], wherein X is any amino acid.

10. The fusion protein of any of claims 1-6, wherein the C-degron peptide comprises a CL1, a CL2, a CL6, a CL9, a CLIO, a CL11, a CL12, a CL15, or a CL16 sequence or a variant thereof.

11. The fusion protein of any of claims 1-6 and 10, wherein the C-degron peptide comprises the sequence set forth in any one of SEQ ID NOS: 1 and 39-46, a contiguous portion of any one of SEQ ID NOS: 1 and 39-46 of at least 4 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing.

12. The fusion protein of any of claims 1-11, wherein the C-degron peptide comprises a CL1 sequence or a variant thereof.

13. The fusion protein of any of claims 1-12, wherein the C-degron peptide comprises the sequence set forth in SEQ ID NO: 1, a contiguous portion of SEQ ID NO: 1 of at least 4 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing.

14. The fusion protein of any of claims 1-13, further comprising one or more additional vaccine epitopes.

15. The fusion protein of any of claims 1-14, wherein the C-degron peptide is located C-terminal to the vaccine epitopes.

16. The fusion protein of any of claims 1-15, wherein the vaccine epitope comprises an infectious disease vaccine epitope, optionally a viral vaccine epitope.

17. The fusion protein of any of claims 1-16, wherein the vaccine epitope comprises a cancer epitope.

18. The fusion protein of claim 17, wherein the cancer epitope is a cancer neoantigen epitope.

19. The fusion protein of claim 17 or 18, wherein the cancer neoantigen epitope comprises a cancer epitope selected from among MEI, M26, Gludl, Mtchl, Ml 8, and E2f8.

20. The fusion protein of any of claims 17-19, wherein the vaccine epitope independently comprises a sequence selected from the sequence set forth in SEQ ID NOS:2-8, a contiguous portion of a sequence selected from the sequence set forth in SEQ ID NOS:2-8 of at least 8 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing.

21. The fusion protein of any of claims 1-20, further comprising one or more peptide linkers.

22. The fusion protein of claim 21, wherein the one or more peptide linkers are located between the vaccine epitope and the C-degron peptide.

23. The fusion protein of claim 21 or 22, wherein the one or more peptide linkers are located between different vaccine epitopes.

24. The fusion protein of any of claims 21-23, wherein the one or more peptide linkers independently comprises a natural linker comprising 5 or more adjacent amino acids that naturally occur in the N- terminal or C-terminal of the vaccine epitope.

25. The fusion protein of any of claims 21-24, wherein the one or more peptide linkers independently comprises a natural linker comprising 8, 9, 10, 11, 12, 13, 14, 15, or 16 or more adjacent amino acids that naturally occur in the N- terminal or C-terminal of the vaccine epitope.

26. The fusion protein of any of claims 21-25, wherein the one or more peptide linkers independently comprises the sequence set forth in any one of SEQ ID NOS:28-38, a contiguous portion of any one of SEQ ID NOS:28-38 of at least 8 amino acids in length, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to any of the foregoing.

27. The fusion protein of any of claims 1-26, wherein when the fusion protein is expressed in a subject, an immune response to the vaccine epitope is increased compared to a subject without expression of the fusion protein.

28. The fusion protein of claim 27, wherein the immune response comprises CD4+ T cell response, CD8+ T cell response and / or antibody response.

29. The fusion protein of claim 27 or 28, wherein the immune response comprises CD4+ T cell response or CD8+ T cell response.

30. A nucleic acid construct encoding the fusion protein of any of claims 1-29.

31. The nucleic acid construct of claim 30, further comprising a translation initiation element.

32. The nucleic acid construct of claim 31, wherein the translation initiation element is an internal ribosome entry site (IRES) or a Translation Initiator of Short 5' UTR (TISU) element.

33. The nucleic acid construct of claim 31 or 32, wherein the translation initiation element comprises the sequence set forth in SEQ ID NO:27, or a sequence that has at least at or about 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to the sequence set forth in SEQ ID NO:27.

34. The nucleic acid construct of any of claims 30-33, wherein the nucleic acid comprises an RNA.

35. The nucleic acid construct of any of claims 30-33, wherein the nucleic acid comprises a circular RNA.

36. The nucleic acid construct of any of claims 30-33, wherein the nucleic acid comprises a linear RNA.

37. The nucleic acid construct of any of claims 30-33, wherein the nucleic acid comprises a cleaved linear RNA comprising a hydroxyl group at the 5' terminus, and a 2', 3'- cychc phosphate at the 3' terminus.

38. The nucleic acid construct of any of claims 30-33, wherein the nucleic acid comprises a messenger RNA.

39. The nucleic acid construct of any of claims 30-33, wherein the nucleic acid comprises DNA.

40. A composition comprising the fusion protein of any of claims 1-29 or the nucleic acid construct of any of claims 30-39.

41. The composition of claim 40, wherein the composition is a pharmaceutical composition.

42. The composition of claim 40 or 41, wherein the composition comprises a pharmaceutically acceptable excipient.

43. The composition of any of claims 40-42, wherein the composition comprises a lipid nanoparticle (LNP).

44. The composition of any of claims 40-42, wherein the composition comprises a lipoplex (LPX).

45. A method of vaccinating a subject, the method comprising administering the fusion protein of any of claims 1-29, the nucleic acid construct of any of claims 30-39, or the composition of any of claims 40-44, to the subject.

46. A method for enhancing vaccine epitope presentation to elicit an immune response in the subject, the method comprising administering the fusion protein of any of claims 1-29, the nucleic acid construct of any of claims 30-39, or the composition of any of claims 40-44, to the subject.

47. The method of claim 45 or 46, wherein the subject has a disease or disorder.

48. A method of treating a disease or disorder in the subject, the method comprising administering the fusion protein of any of claims 1-29, the nucleic acid construct of any of claims 30-39, or the composition of any of claims 40-44, to the subject.

49. The method of any of claims 45-48, wherein an immune response to the vaccine epitope is increased compared to a subject without expression of the fusion protein.

50. The method of claim 49, wherein the immune response comprises CD4+ T cell response, CD8+ T cell response and / or antibody response.

51. The method of claim 49 or 50, wherein the immune response comprises CD4+ T cell response or CD8+ T cell response.

52. The method of any of claims 45-51, wherein the method prevents or reduces the severity of a disease or disorder associated with the vaccine epitope in the subject.

53. The method of any of claims 47-52, wherein the disease or disorder is an infectious disease, optionally a viral infection.

54. The method of any of claims 47-53, wherein the disease or disorder is cancer.

55. The fusion protein of any of claims 1-29, the nucleic acid construct of any of claims 30-39, or the composition of any of claims 40-44 for use in vaccinating a subject, wherein the fusion protein, the nucleic acid construct or the composition is administered to the subject.

56. The fusion protein of any of claims 1-29, the nucleic acid construct of any of claims 30-39, or the composition of any of claims 40-44 for use in enhancing an immune response to a vaccine epitope in a subject, wherein the fusion protein, the nucleic acid construct or the composition is administered to the subject.

57. The fusion protein of any of claims 1-29, the nucleic acid construct of any of claims 30-39, or the composition of any of claims 40-44 for use in treating a disease or disorder in a subject, wherein the fusion protein, the nucleic acid construct or the composition is administered to the subject.

58. Use of the fusion protein of any of claims 1-29, the nucleic acid construct of any of claims 30-39, or the composition of any of claims 40-44 in the manufacture of medicament for vaccinating a subject, wherein the medicament is administered to the subject.

59. Use of the fusion protein of any of claims 1-29, the nucleic acid construct of any of claims 30-39, or the composition of any of claims 40-44 in the manufacture of medicament for enhancing an immune response to a vaccine epitope in a subject, wherein the medicament is administered to the subject.

60. Use of the fusion protein of any of claims 1-29, the nucleic acid construct of any of claims 30-39, or the composition of any of claims 40-44 in the manufacture of medicamentfor treating a disease or disorder in a subject, wherein the medicament is administered to the subject.